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          kpfpDk; FiwapDk; Neha; nra;Ak;E}NyhH  
tsp Kjyh vz;zpa %d;W 
‘kz;bzpe;j epyDk;  
epyNde;jpa tpRk;Gk; 
tpRk;G ijtU tspAk; 
tspj; jiy,a jPAk; 
jPKuzpa ePUnkd; whq;F 
Ik;ngUk; G+jj; jpaw;if Nghy” 
- njhy;fhg;gpak; 
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kz; + kz;   -  vYk;G   ePH + kz;  - %is 
kz; + ePH  - khkprk;   ePH + ePH  - rpWePH 
kz; + jP  - Njhy;   ePH + jP  - nfhOg;G 
kz; + fhw;W - euk;G    ePH + fhw;W  - Rf;fpyk; 
kz; + Mfhak; - kapH    ePH + Mfhak; - cjpuk; 
 
jP + kz;  - ikJdk;   fhw;W + kz; - fplj;jy; 
jP + ePH  - Nrhk;gy;   fhw;W + ePH  - ,Uj;jy; 
jP + jP   - epj;jpiu   fhw;W + jP  - elj;jy; 
jP + fhw;W  - mfq;fhuk;   fhw;W + fhw;W - Xly; 
jP + Mfhak; - gak;    fhw;W + Mfhak; - jhz;ly; 
 
Mfhak;+ kz; - khr;rhpak; 
Mfhak; + ePH - kjk; 
Mfhak;+ jP  - Nkhfk; 
Mfhak;+ fhw;W - cNyhgk; 
Mfhak;+ Mfhak; - fhk FNuhjk; 
 
tsp – fhw;W + Mfhak; 
moy; - jP  
Iak; - kz; + ePH 
 
 
 
 
INTRODUCTION 
 E}NyhH> mwptH> MrPtfH> rpj;jH vd ntt;NtW fhyf; fl;lq;fspy; 
jkpoHfs; njhlHe;J jq;fspd; tsHr;rp epiyapy; nka;Q;Qhdpfshf 
jpfo;e;Js;s tuyhWfs; ,d;Wk; vQ;rpf; fplf;fpwJ. mtHfs; tFj;j 
(my;yJ) gd;ndLq;fhykhf jkpohpd; tho;tpaNyhL gpizj;j xd;Wjhd; 
rpj;j kUj;Jtkhk; jkpo; kUj;Jtk;. 
 ‘epyk; ePH> jP> tsp> tpRk;Nghile;Jk; fye;j kaf;fk; cyfkhjypd;” 
- njhy;fhg;gpak; 
Ik;G+jj;jpdhy; cUthdNj mz;lKk;> gpz;lKk; 
 ‘jhjfpAk; fl;bAkpl;L kw;Wk; $l;l  
 kJf;fdp gpwe;jhq;F rhw;wpLk; 
 G+jj;JzHT Njhd;wp mt;tg; G+jtop nrd;W  
 giwNahirapy; nfLk;” 
- kzpNkfiy 
 
jhjfpg;G+> gidnty;yk;> mhprp ,tw;iw xU Fwpg;gpl;l 
tpfpjhr;rhuj;jpy; xd;W fye;J itf;f Nghij Vw;gLj;jf;$ba kJ 
gpwf;Fk;. Mdhy; jhjfpg;G+> gidnty;yk;> mhprp ,tw;iw jdpj;jdpNa 
cl;nfhs;Sk; NghJ ve;j tpjkhd NghijAk; Vw;glhJ. ,jpypUe;J 
Gyg;gLtJ ahnjdpy; Ik;G+jq;fs; Fwpg;gpl;l tpfpjhr;rhuj;jpy;> rpy 
#o;epiyapy; xd;W NrUk; NghJ Rit gpwf;fpwJ. Rit epiwe;j czit 
cz;Zk; NghJ mit VO clw;fl;Lfshfp capiu (tsp> moy;> Iak;) 
tsHf;fpwJ.  
,e;j gQ;rG+j gQ;rPfuzNk cWg;Gfshf> Rug;Gfshf> njhopy;fshf> 
nray;fshf> czHTfshf khw;wk; ngw;W gpz;lj;ij nray;gLj;Jfpd;wJ. 
Ik;G+jj;jj;Jtj;jpd; rkepiyapy; Vw;gLk; Vw;wj;jho;TfNs Neha; 
epiyfs; (cly; kw;Wk; kdk;) mtw;iw rkepiyg;gLj;Jk; mtpo;jq;fSk;> 
mtpo;j KiwfSk;> $l Ik;G+j mbg;gilapy; mike;jpUg;gNj ek; rpj;j 
kUj;Jtkhk; jkpo; kUj;Jtj;jpd; jdpj;JtkhFk;. 
,j;jifa Ez;khz; Eio Gyj;jpw;F rhd;whf tpsq;Fk; ,e;j 
kUj;Jtk; clw;gpzp> csg;gpzp kw;Wk; Neha;j; jLg;Gf;F mtpo;jj;ijf; 
fle;J 
 
 
 
 
‘kWg;gJ rhit kUj;njd yhNk”  - jpU%yH 
vd nka;Q;Qhdj;jpw;F tpj;jpl;L> ,aw;ifr; rPw;wq;fis 
gd;ndLq;fhykhf fle;J jkpohpd; tho;tpaNyhL fye;J ,Uf;fpd;wJ. 
mtw;iw mWRit czT> kUj;Jtk;> ,urthjk;> thdpay; vd mLf;fpf; 
nfhz;Nl Nghfyhk;. 
 ‘kpfpDk; FiwapDk; Neha;nra;Ak; E}NyhH 
 tspKjyh vz;zpa %d;W”   - jpUf;Fws; 
tsp> moy;> Iak; vd;w capHj;jhJf;fspd; kpF Fzk;> Fiw FzNk 
Neha;fSf;Ff; fhuzk; vd;fpwJ jpUf;Fws;. NkYk; rpj;jHfs; Neha;fspd; 
fhuzj;ijAk;> 4448 vd Neha;fspd; vz;zpf;iffisAk;> mf kUj;Jtk; 
32> Gw kUj;Jtk; 32 vd;W mtw;wpf;fhd kUj;Jt KiwfisAk; 
tFj;Js;sdH.  
,e;j kzp> ke;jpu mtpo;j Kiwikfs; 
Ma;Tf;$lj;jpy; my;y 
nka;Qhdj;jhy;> 
 vy;yh kf;fSf;Fk; 
 vy;yh tajpdUf;Fk; 
 vy;yh fhy#o;epiyf;Fk; 
 vy;yh Neuj;jpw;Fk; 
 vy;yh khw;wq;fSf;Fk; 
 Vw;wthW tbtikf;fg;gl;lJ. 
,JNt rpj;j kUj;Jtj;jpd; rpwg;G. 
 tiuaWf;fg;gl;l 4448 Neha;fspy; cjputhjRNuhzpjNehAk; xd;W. 
RkhH 0.5 - 1% kf;fs; ,e;j Nehapdhy; ghjpf;fg;gl;Ls;sdH. Mz;fis 
tpl ngz;fspy; ,e;Neha; mjpfkhf fhzg;gLfpwJ   (Mz;:ngz;- 1 : 4) 
thj Neha;fspy; xd;whd cjputhjRNuhzpjNeha; Ma;Tf;fl;Liuf;fhf 
NjHe;njLf;fg;gl;lJ. ,e;Nehapdhy; ghjpf;fg;gl;ltHfspd; rpWtpuy; 
%l;Lfs;> nghpa %l;Lfspy; typ> tPf;fk; Vw;gl;L md;whl gzpfisf; $l 
nra;a Kbahky; tUe;Jfpd;wdH. vdNt ,e;j Ma;Tf;fl;Liuapy; 
cjputhjRNuhzpj Nehapid Fzg;gLj;j Ntq;ifg;gl;ilj; ijyk; kw;Wk; 
kapypwfhjp vz;nza; NjHe;njLf;fg;gl;Ls;sJ. 
  
 
 
 
 
AIMS AND OBJECTIVES 
 
 
AIM: 
 The aim of this dessertation is to bring out the most acceptable, applicable, 
and affordable drug without the side effects from Siddha system of medicine for 
the disease Uthiravathasuronitham(Rheumatoidarthritis)   
                                                                                                             
OBJECTIVES: 
1. Primary objectives 
To evaluate the clinical efficacy of Myeliragathi ennai as internal medicine 
and Vaengaipattai thylam as external medicine for the disease Uthira vatha 
suronitham. 
2. Secondary objectives 
 To study the efficacy of additional therapies like varmam, Thokkanam 
(massage) and asanas in treating the disease along with the internal and 
external medicines. 
 To discuss the various literary evidences in both Siddha and modern text 
books for the diseases Uthiravathasuronitham. To confirm the diagnosis 
in Siddha system with the help of modern parameters. 
 To know the extent of correlation of features given under 
Uthiravathasuronitham with the features of Rheumatoid arthritis there 
by showing the highness of siddhars. 
 To know the chemical and phytochemical analysis of the selected drug. 
 To study the Pharmacological analysis of the selected drug. 
 
 
 
 
 To have an idea of an incidence of Uthiravathasuronitham with 
reference of age, sex, Socio economic status, habits and family history 
related to any psychosomatic problems, land where they live (nilam) and 
climatic changes (Paruva  Kalam). 
 To make an awareness among the patients in order to avoid further 
degeneration. 
 
  
 
 
 
 
REVIEW OF LITERATURE 
SIDDHA  LITERATURE 
cjputhj RNuhzpjk; 
ngaHf;fhuzk;: 
cjpuk; - FUjp> ,uj;jk; 
thjk; -   ce;jpapd; fPo; gpwe;J clk;G KOtjpYk; gutp Rthrk;> 
grp> jhfk; KjypaitfSf;F Mjhukhf ,Ue;J 
nfhz;L gy tpfhuq;fis Vw;gLj;jpf; nfhz;bUf;Fk; 
Kg;gpzpfspnyhd;W. 
 euk;G Jthuq;fspy; nfl;l ePH jq;fp jirapy; Cwp 
mjdhy; thA mjpfhpj;J rHthq;fj;ijAk; gw;wp 
epw;FNkhH Neha;. ,jdhy; if> fhy;> cly; cisAk;. 
 clYf;F ahnjhU jPq;Fk; Nehplhjgb vq;Fk;   
jhJf;fisnay;yhk; ghJfhf;Fk; XHtpj rf;jp.  
 RNuhzpjk; - cjpuk; (blood) kfspH #jfk; (menstrual blood) 
Nehapd; ngaHf;fhuzk;: 
1. cjpuk; - ,e;Nehapy; cjpuk; Nfliltjhy; (RA Factor  Hb 
ESR CRP). 
2. thjk; - thj Neha;fspy; xd;W 
3. RNuhzpjk; - ngz;fspy; mjpfkhff; fhzg;gLtjhy;  
 
Fwpg;G: 
 cjputhjRNuhzpjk; vd;Dk; ,e;Nehapidg;gw;wp A+fp itj;jpa 
rpe;jhkzp kw;Wk; guuhrNrfuk; vd;Dk; ,uz;L E}ypYk; fhzg;gLfpwJ. 
,e;Nehapid tspmoy;fPy;thA vd;Wk; rpyH Fwpg;gpLtH.  
 fz;Zrhkp itj;jpa Nrfuk; vd;Dk; E}ypy; fhsNkfehuhazr; 
nre;J}uk; vd;w kUe;jpd; jPUk; Neha;fspy; cjputhjk; vd ,e;Neha; 
Fwpg;gplg;gLfpwJ. fz;Zrhkp itj;jpa Nrfuj;jpy; Fwpg;gplg;gl;Ls;s 
cjputhjk; vd;w nrhy;ypw;Fk; j.tp. rhk;grptk; gps;is mfuhjpapy; 
fhzg;gLk; cjputhjk; vd;w nrhy;ypd; nghUSf;Fk; rpy xw;Wikfs; 
 
 
 
 
cs;sJ. Mdhy; j.tp. rhk;grptk;gps;is mfuhjpapy;> ,e;Neha; Mz;fsplk; 
mjpfkhf fhzg;gLfpwJ vd;w Fwpg;G tUfpwJ.  
 mjdhy; ,e;j Ma;Tf;fl;Liuapy; A+fp itj;jpa rpe;jhkzp kw;Wk; 
guuhrNrfuk; vd;w E}y;fspy; Fwpg;gplg;gLfpw cjputhjRNuhzpjk; vd;Dk; 
NehAk; mjd; FwpFzq;fSk; fUj;jpy; vLj;Jf; nfhs;sg;gLfpwJ.  
ntt;NtW E}y;fspy; thj Neha;fspd; tifg;ghL: 
1. m\;lhq;f rq;fpufk;    - 85 thjk; 
2. Neha; ehly; ghfk; - 2    -  81 thjk; 
3. NjiuaH thflk;    - 81 thjk; 
4. jd;te;jphp itj;jpak;    - 81 thjk; 
5. [Ptuf;\hkpHjk;     - 80 thjk; 
6. mfj;jpaH 2000     - 80 thjk; 
7. NghfH itj;jpak;    - 84 thjk; 
8. mfj;jpaH FUehb    - 84 thjk; 
9. mfj;jpaH itj;jpa  
,uj;jpdr; RUf;fk; 500   - 84 thjk; 
10. guuhrNrfuk;     - 80 thjk; 
11. A+fp itj;jpa rpe;jhkzp ngUE}y; 800 - 84 thjk; 
12. A+fp itj;jpa fhtpak;   - 80 thjk; 
Neha; tUk; top: 
cjputhjRNuhzpjNehia Vw;gLj;Jk; %d;W fhuzpfshff; 
fUjg;gLgit 
1. czT 
2. gof;f tof;fq;fs; 
3. Rw;Wr;#oy; 
1. czT 
 ‘jhndd;w frg;NghL JtHg; Giwg;G 
   rhjfkha; kpQ;RfpYQ; rikj;j tz;zk; 
  Mnkd;w thwpde; Grpj;j yhYk; 
  Mfhaj; J}wyJ Fbj;jyhYk; 
 ghndd;w gfYwf;f apuh tpopg;G 
  gl;bdpNa kpfTWjy; ghunka;jy; 
 
 
 
 
 Njndd;w nkhopahH Nkw;rpe;ij ahjy; 
  rPf;fpukha; thjkJ nrdpf;Fe; jhNd”. 
- A+f itj;jpa rpe;jhkzp ghly; 
 
frg;G> JtHg;G> fhuk; NrHe;j czit mUe;Jjy;> Mwpd czit 
cz;zy;> Njq;fpa ePiu mUe;Jjy;> gfypy; J}q;fp ,uT tpopj;jpUj;jy;> 
gl;bdp fplj;jy;> kpFe;j Rikiaj; J}f;Fjy;> ngz;zpd; Nky; kpFe;j 
tpUg;gk; nfhs;sy; Nghd;wit fhuzq;fshfpd;wd. 
 ‘tsp jU fha;fpoq;F tiutpyh Japyy; Nfhio 
  Ksp japH Nghd;kpFf;F Kiwapyh Tz;b Nfhly; 
  FspHjU tspapw; Nwfq; Fdpg;Gw Tyty; ngz;bH 
  Fspj;jU kaf;fk; ngw;NwhH fb nray; fUtp ahkhy;” 
- rghgjp ifnaL 
thjf; Fw;wj;ij kpifg;gLj;jf; $ba fpoq;F tiffs;> 
FspHr;rpiaj; juf;$ba gjhHj;jq;fs; kpFjpahf cz;zy;> FspHe;j 
fhw;wpy; ,Uj;jy;> kioapy; eidjy;> gdpf;fhw;W NkNy tpOjy;> kiyg; 
gpuNjrq;fspy; trpj;jy; kw;Wk; guk;giuapd; fhuzkhfTk; Njhd;Wk;. 
 
‘fhyq;fz; khwp Az;Zq; fhhpaj; jhYe; jz;zPH 
 rhyNt aUe;jpd jhYk; re;jpap Yl;fhHe; jhYk; 
 Nfhykhk; Gspg;G nea;iaf; Fiwtw tUe;jp dhYk; 
 thythH Kiyey; yhNs thjKw;g tpf;Fq; fhNz” 
- A+fp itj;jpa rpe;jhkzp 
FspH fhw;wpy; cl;fhHe;jpUj;jy;> Gspg;G> nea; cztpy; kpFjpahf 
NrHj;Jf; nfhs;sy;> fhyk; jtwp cz;zy; Mfpa fhuzq;fshy; thj Neha; 
Njhd;Wk;. 
 
2. gof;ftof;fq;fs; 
 ,akk;> epakk; vDk; gof;f tof;fq;fs;> tpjpfspy; jtWtjhy; 
Neha;fs; Njhd;Wk;. 
  ‘nta;apypy; elf;ifahYk; kpfj;jz;zPH Fbf;ifahYk; 
    nra;apio kfspiur; NrHe;jDg tpf;ifahYk; 
 
 
 
 
   igaNt cz;zhikahYk; ghfw;fha; jpd;ifahYk; 
   ijaNy thjNuhfk; rdpf;F nkd;wwpe;J nfhs;Ns” 
- NjiuaH thflk; 
 
 #hpa ntg;gj;jpy; mjpf njhiyT elg;gjhYk;> mjpf jz;zPH 
Fbg;gjhYk;> mjpf msT ghfw;fha; rhg;gpLtjhYk; tsp Neha;fs; 
Njhd;Wk;. 
 ‘fhzNt kpfTz;lhYq; fUJgl;bdp tpl;lYk; 
   khdid ahHfz; Nkhfkpwf;fpD kpFe;jpl;lhYk; 
  Mzt kyq;flik aq;qNd tplhjjhYk; 
  thDjd; kley;yhNs thjq;Nfh gpf;Fq;fhNz” 
- A+fp itj;jpa rpe;jhkzp 
mjpf msT cz;zy;> gl;bdp fplj;jy;> Mztk; mjpfhpj;jy; 
Mfpatw;why; thjNeha;fs; Njhd;Wk;. 
 
3. Rw;Wr; #oy; 
  ‘thjtHjd fhyNkNjh ntd;dpy; 
   kUTfpd;w Mdp fw;fl khjk; 
   Mjidg; grpNahL fhHj;jpif jd;dpy; 
   mlUNk kw;w khjq;fs; jd;dpy; 
   NghfNt rkpf;fpdpw; fhy khFk;”. 
- A+fp rpe;jhkzp 
 
tsp NehahdJ Mzp Kjy; fhHj;jpif khjq;fspy; mjpfkhf 
fhzg;gLk;. 
   
 
 
 
 
 
 
 
 
 
 
 
‘gJkj;ij G+f;f itf;Fk; ghDkpff;fhAk;  
    KJntdpypw;G tpw;wPePH Kw;Wk; - fJnkd 
   tw;Wk; fgkq;Fk; thAkpFk; tho;khe;jHf; 
   Fw;w eypf;Nfjpnjd; NwhJ” 
- rpj;j kUj;Jthq;fr; RUf;fk; 
 
KJNtdpw; fhyj;jpy; #hpa ntg;gj;jpd; fhuzkhf ngU thhpahd 
ePH Mtpahf;fg;gl;L cyfj;jpy; twl;rp epyTk;. mJ Nghy ekJ clypYk; 
twl;rp vw;gl;L tsp Neha; tUtjw;F fhuzkhfpd;wJ. 
 
 
 
 
Kf;Fw;w NtWghL: 
 
Neha; tUk; top 
taJ 
czT 
gof;ftof;fq;fs; 
fhykhWghL 
 
 moy;          tsp    Iak;  
 rhjfk;      tpahdd;    re;jpfk;  
                                      mghdd; 
    
                              cjputhjRNuhzpjk; 
 
 
thj Nehapd; nghJf;FwpFzq;fs; 
tsp kpFjypd;  ,ay;G(thA gpuNfhgk;) 
 jf;fthA Nfhgpj;jhy; re;J Tise;J jiyNwhth 
kpf;f %hp nfhl;lhtptpl;lq; nfhpA kyq;fl;Lk; 
xf;f euk;Gjhd;Klq;F Kyh;e;J tha;eP %wptUk; 
kpf;f FspUk; eLf;fKkhk; Nkdp Fd;wp tUq;fhNd 
       -Njiuah; thflk; 
 
thAtpd; gpuNfhgj;jhy; 
 vd;G %l;Lfspy; Nehf;fhL 
 jiytyp 
 kpfTk; type;j nfhl;lhtp 
 kyk; fl;Lg;gLk; 
 
 
 
 
 euk;Gfs; jd; ,ay;G khwp Klq;fYk;>tusYk; cz;lhjy; 
 cly; ,isf;Fk;. 
Nghd;w FwpFzq;fs; cz;lhFk;. 
thjj;jpd; Fzk; 
 ‘thjj;jpd; FzNk njd;dpy; kaq;Fe;jpaq;Fk; kyh; rptf;Fk;  
ghjq; Fsph;e;J rUthq;fk; gw;wp elf;F Kfq;fLf;FQ;  
rPjj;JlNd tapW Gz;zhQ; rphpg;gpj;Je;njwp %r;rhk;  
Nghjj;jz;zPh; jhd; thq;Fk; GfOk; gQ;r FzkhNk” 
‘thjj;jpd; Fzj;ijf; Nfz;kpd; tapW}Jk; nghUkpf; nfhs;Sk;  
jhJw;w Tlk;Giffhy; re;Jfs; fLg;GNjhZk;  
jPJw;w rpWePh; jhDQ; rpte;Jly; fLj;J tPOk; 
NghJw;w Tg;Grkha; NghjTk; grpj;jplhNj” 
‘fhy;if fLf;fe; jpkpUz;lhq; fz;Ze; J}q;fpr; Nfhgpf;Fk; 
NfhyQ;nrhpA kq;fnky;yhq; Fsph;e;j rw;W fzq; nfhs;SQ;  
rPykpFe;J rPh;fhzpy; rpWePh;tw;wp tUkpfNt  
khyj; jlq;fz; khdnzaha; khNj thjNuhfkpNj” 
      -mfj;jpah;  2000 
 kaf;f Kz;lhFk; 
 fz;fs; rptf;Fk;  
 fhy;fs;> rpy;ypl;L gpd;dh; cly; Fsph;e;J tpLk;  
 Kfj;jpy; Fj;J typNaw;gLk; 
 tapWGz;zhfp rPjk; tpOk;  
 ngU%r;RKz;lhFk;  
 jz;zPh; jhfNkw;gLk;. 
 tapW Cjpg;nghUkYz;lhFk;.  
 if> fhy;> clk;G njhilapLf;F Kjyhd ,lq;fspy; fLg;G 
(Ntjid) mjpfhpf;Fk;.  
 rpWePh; rpte;J fLg;Gld; ntspahFk;.  
 grp ke;jpf;Fk;. 
 iffhy;fspy; kjkjg;Gld; NtjidAz;lhk;.  
 fz;fisr; Rw;wpYk; tPf;fKz;lhFk;  
 clypy; Fsph;r;rpAz;lhk; 
 njhilapLf;fpy; tPf;fk; fhzg;gLk; 
 
 
 
 
 rpWePh; mstpy; FiwAk; 
,itfs; thjk; mjpfhpj;jypd; FwpfshFk;. 
thjf;$W 
‘Mr;rg;gh apjd;  eyjhar; nrhd;Ndhk; 
 Mfhfh ape;E}y;jhd; fhtpafhz;gpj;jjpy;  
thr;rg;gh thjj;jpd; $iwr; nrhd;Ndhk; 
 thjkjpd; thAepiy kaq;fpg; NghFk; 
fhf;fg;gh fyq;fpaJ jpaq;fpg;NghFk; 
 fz;kzpNa tJf;F kj;jpge;jhd; Nfsu 
khr;rg;gh kf;fpdpjhd; kJ Nthnlhf;f 
 khh;f;fkjha; $btpid ahLk;ghNu” 
      -mfj;jpa Kdpth;thjfhtpak; 
 thA jd; ,Ug;gplk; tpl;L khWk; 
 ke;jk; cz;lhFk; 
gpj;jKk; Nrh;e;J mjpfhpf;Fk;  
thjk; kpF Fzk; :  
‘mwpatpk; %d;wpd; jd;ik nrhd;dhh;ee;jp  
vwpa ey;thj nkwpf;Fq; Fzq;NfS 
Fwpnadf; iffhy; Fisr;R tpyhr;re;J............” 
-jpU%yehadhh; rpfpr;rhuj;djPgk;.  
 
thj Nehapy; Fj;jy; typ> re;Jfs; Nehjy;> tapW nghUky;> 
Flypiwr;ry;> kyr;rpf;fy; Nghd;w FwpFzq;fs; Njhd;Wk;.  
        ‘thjtPW md;dkpwq;fhJ fLg;Gz;lhk; tz;zKz;lhk; 
 NkhJfl;F Nuhfk; RuKz;lh kpUkYkh Kwq;fhnjd;Wk; 
 XJjhpa thjkdyhF eLf;fKz;lhk; nghUs; fsah;e;j  
 jPnjdNt euk;gpj;J re;Jfs; NjhWq;fLf;Fe; jpKe;jhNd” 
             -Njiuah; thflk;. 
 
 
 
 
 
thjk; kpFk;NghJ grpapd;ik> cly; fLg;G> Ruk;> ,Uky;> cwf;fkpd;ik> 
cly; eLq;fy;> euk;Gj;jsh;r;rp> re;Jfs; NjhWk; Filjy; Nghd;w 
FwpFzq;fs; Njhd;Wk;.  
  
       ‘jf;f thA Nfhgpj;jhy; re;Jise;J #iyNehth  
 kpf;f nfhl;lhtp tpl;lq; nfhpA kyq;nfl;Lk; 
 xf;f euk;G jhd; Klq;F kyh;e;J tha; eP&wptUk; 
 kpf;f FspUk; eLf;fkha; Nkdp Fd;wp tUq;fhNd” 
                 -Njiuah; thflk;.  
thjk; kpFk;NghJ %l;Lfs; NjhWk; typ> kpFe;j nfhl;lhtp> 
kyr;rpf;fy;> euk;Gj;jsh;r;rp> tha; ePUwy;> kpff;Fsph;r;rp> cly;  eLf;fy;> 
Nghd;w FwpFzq;fs; Njhd;Wk;.  
Fwpg;G:  
thj Neha;fspy; xd;whd cjputhjRNuhzpjj;jpy; nghJthd thj 
Neha; Fwp Fzq;fSld; jdpj;jd;ikahd FwpFzq;fSk; NrHe;Nj 
fhzg;gLk;. 
  
 
 
 
 
cjputhjRNuhzpjk; 
FwpFzq;fs;: 
  
 
‘itfpjkha;f; fZf;fhY Koq;fhy; jhDk;  
  kw;flQ; re;JGw tbAk; tPq;fpr; 
  nra;fpjkhQ; rpWtpuy;fs; kpfTk; nehe;J 
  rpe;ijjL khwpNa rypg;Gz; lhFk; 
   igfpjkhk; igj;jpaj;jpy; thj kpQ;rpg; 
  ghukha; cw;gtpj;J moYz; lhFk; 
 ca;fpjkha; mrdkJ jhDk; Ntz;lh 
  cjputhj RNuhzpjj; JzHr;rp ahNk”. 
 
nghUs;  
 
fZf;fhy; - fhy;guL (Anklejoint)  
Koq;fhy; - fhy;%l;L (Kneejoint)  
 kw;flk; - Fuq;F> miw (Hipjoint) 
Gwtb  - Gwq;fhy;> fhypd; Nky; gFjp  
(Dorsal aspect of foot) 
rpWtpuy;fs;- if> fhy; tpuy;fs; (Smaller joints of fingers) 
nehe;J - Jd;gj;ij jUjy;  
 rpe;ij - kdk; (Thought) 
rypg;G  - NrhHT> ntWg;G  
igj;jpak; - Mental Disturbance 
cw;gtpj;J  - cw;gj;jpahjy; (Generated)  
moy;  - jP> moy; Fw;wk; 
 mrdk; - czT   
 
 
 
 
 
FwpFzq;fs;: 
1. fZf;fhy;> Koq;fhy;> re;Jfs; (Joints), Gwtb (Dorsum of foot) 
,itfspy; tPq;Fk;. (Swelling in Ankle joint, Knee joint, Dorsum of 
foot and other joints). 
2. rpW tpuy;fs; kpfTk; nehe;J fplf;Fk;. (Sever pain in the fingers ie 
along metacarpophalangeal joints & Proximal interphalangeal joints). 
3. rpe;ij jLkhwpNa (State of mental confusion). 
4. rypg;Gz;lhFk; (Fatiguability). 
5. igj;jpaj;jpy; thj kpQ;rp (Along with mental confusion Vatham is 
increased). 
6. moy; cz;lhFk; (Azal (Pitham) is increased). 
7. grpapd;ik> czT kWg;G (Loss of appetite, dislike of food). 
 
 
‘nghHrPNj Tjpu thj RNuhzpj Koq;fhy; jhDk; 
 nghw;fizf; fhYk; re;Jk; Gwtb jhDk; tPq;fp 
 ew;fZ tpuy;f ndhe;J eLg; gapj;jpa thjj;jpy; 
 cw;gtf; FzKKz;lh KWE}ypw; nrhd;d jhNk” 
- guuhrNrfuk; 
-  
cjputhjRNuhzpjj;jpy; 
1. Koq;fhy;> fZf;fhy;> re;Jfs;> Gwtb (Dorsum of foot) Mfpa 
,lq;fspy; tPq;Fk;. 
2. fZf;fs; cs;s tpuy;fs; NjhWk; typAz;lhFk;. (Pain in meta 
carpophalangeal and interphalangeal joints). 
3. gapj;jpa thjj;jpy; fhZk; Fzq;fs; cz;lhFk;. (Osteoporosis). 
 
cjputhjRNuhzpjj;jpy; fhzg;gLk; FwpFzq;fs; etPd 
kUj;Jtj;jpy; tpthpf;fg;gl;Ls;s Rheumatoidarthritis Nehapd; 
FwpFzq;fSld; ngUk;ghYk; xj;Jg; Nghfpd;wJ. 
 
 
 
 
 
clw;fl;Lfs; 
cz;l czTfs; Kjy; ehs; rhukhfp> ,uz;lhk; ehs; nre;ePH Mfp 
,t;thW Vohk; ehs; Rf;fpykhf khWfpwJ. vl;lhk; ehs; clYf;F td;ikj; 
jUfpwJ. cjputhjRNuhzpjNehapy; 7 clw;fl;LfSk; ghjpg;gile;J Neha; 
cz;lhfpwJ. 
t. 
vz; 
clw;fl;Lfs; njhopy; ghjpg;G 
1. rhuk; 
cliyAk;> kdijAk; 
Cf;fKwr; nra;Ak; 
cly; tUj;jk;> thl;lk; 
2. nre;ePH mwpT> td;ik> xsp 
twl;rp> euk;Gj;jsHr;rp  
ESR  CRP  RA Factor + 
Hb  Lymphocytes  
3. Cz; 
clYf;F cUtj;ijj; 
je;J mjd; 
njhopw;fpzq;f 
mikj;jy; 
Ik;nghwpfspd; NrhHT 
Tendosynovitis Rupture of 
Tendons 
4. nfhOg;G 
clYWg;Gfs; 
fbdkpd;wp ,aq;f 
mtw;wpw;F 
nea;g;Gg;gir jUk; 
cly; ,isj;jy;> ,Lg;gpy; 
td;ik Fiwjy;. 
Loss of lubrication that 
produces loss of friction in 
between the joints. 
5. vd;G 
clYf;F cWjpiaj; 
je;J> nkd; 
cWg;Gfis 
ghJfhj;jy; 
vd;G %l;Lfspy; typ> Nja;T> 
gw;fspy; Neha;fs;> efk;> kapH 
ntbj;jy;. Bone is eroded by 
granulation tissue. Articular 
cartilage is lysed and invaded 
by Pannus 
6. %is 
vd;gpw;Fs; epiwe;J 
clYf;F td;ikia 
jUfpwJ. 
vd;Gfspy; Jis tpOjy;. 
Osteoporosis and Osteoclastic 
resorption. 
7. 
Rf;fpyk; / 
RNuhzpjk; 
jd;idnahj;j cUtg; 
ngUf;fpw;F 
fhuzkhfp 
fUj;Njhw;wj;jpw;F 
Kf;fpakha; mikAk;. 
Aetiology of Genetic 
Susceptibility in their children / 
or from their parents. 
 
 
 
 
capHj;jhJf;fs; 
tsp> moy;> Iak; %d;Wk; capHj;jhJf;fshFk;.  
‘kpfpDk; FiwapDk; Neha; nra;Ak; E}NyhH 
 tspKjyh vz;zpa %d;W” 
capHj;jhJf;fs; jd; mstpy; kpFe;jhYk;> Fiwe;jhYk; Neha; 
nra;Ak;. ,e;Neha; epiyia Kf;Fw;w NtWghL vd;fpNwhk;. 
cjputhjRNuhzpj Nehapy; fhzg;gLk; Kf;Fw;w NtWghLfs;.  
 
 tsp njhopy; ghjpg;G 
1. gpuhzd; 
%r;R tpLjy;> thq;Fjy; 
njhopy; 
ruk; ghjpg;G> moy; 
Fw;wk; nra;Ak; 
2. mghdd; ky ryj;ij ntspj;js;sy; 
kyr;rpf;fy;> 
tspf;Fw;wk; 
3. cjhdd; 
cztpd; rhuj;ij Mq;fhq;Nf 
epWj;jp> ntspg;gLj;jp> 
fyf;fTk; nra;Ak;. 
,ay;G 
4. tpahdd; 
7200 ehbfspy; nrd;W 
cWg;Gfis ePl;lTk;> klf;fTk; 
nra;Ak;. 
if> fhy;> %l;L 
gFjpfis ePl;b 
klf;f rpukk; 
5. rkhdd; 
jrthAf;fisAk; rkepiyapy; 
itf;Fk;. 
gpw thAf;fspd; 
ghjpg;G 
6. ehfd; 
vy;yh fiyfisAk; fw;Fk;gb 
mwpit vOg;Gk; 
,ay;G 
7. $Hkd; 
ghHit> ,ik nfhl;ly;> 
nfhl;lhtp tplg; gz;Zk; 
,ay;G 
8. fpUfud; kpF grpia cz;L gz;Zk;. grpapd;ik 
9. Njtjj;jd; 
Nrhk;gy; Kwpj;jy;> rz;il 
nfhs;sy; 
ghjpg;G 
10. jdQ;nrad; 
,we;j gpwF %d;whk; ehs; 
clypypUe;J ntspg;gLk;. 
- 
 
 
 
 
 
moy; 
 moy; njhopy; ghjpg;G 
1. mdw;gpj;jk; Mf;fdy; ghjpg;G - grpapd;ik 
2. ,uQ;#gpj;jk; ,uj;jj;ij kpFjpg;gLj;Jk; 
ghjpg;G - 
,uj;jf;FiwT 
3. rhjf gpj;jk; epiwNtw;Wk; gz;GilaJ 
ghjpg;G - %l;Lfis 
nray;gLj;j 
,ayhik 
4. gpuhrf gpj;jk; NjhYf;F xspiaj; jUtJ ,ay;G 
5. MNyhrfgpj;jk; Nehf;foy; ,ay;G 
 
Iak; 
 Iak; njhopy; ghjpg;G 
1. mtyk;gfk; 
kw;w ehd;F Iaq;fSf;Fk; 
gw;Wf; Nfhlhf mikAk; 
ghjpg;G 
2. fpNyjfk; czTg; nghUis <ug;gLj;Jk; ,ay;G 
3. Nghjfk; cztpd; Ritia mwptpf;Fk; ,ay;G 
4. jw;gfk; 
fz;fSf;F FspHr;rpiaj; 
jUk; 
,ay;G 
5. re;jpfk; 
fPy;fspy; epd;W mitfis 
xd;Nwhnlhd;W nghUj;jp 
jsur; nra;Ak; 
ghjpg;G - %l;Lfisr; 
nray;gLj;j rpukk; 
 
fhyepiyfspd; khw;wk;: 
 thjk; gpj;jk; fgk; 
jd;dpiy 
tsHr;rp 
KJNtdpy;  
(Mdp - Mb) 
(June 15 – Aug 15) 
fhHfhyk;  
(Mtzp> Gul;lhrp) 
(Aug 15 – Oct 15) 
gpd;gdp  
(khrp> gq;Fdp) 
(Feb 15 – Apr 15) 
Ntw;Wepiy 
tsHr;rp 
fhHfhyk;  
(Mtzp> Gul;lhrp) 
(Aug 15 – Oct 15) 
$jpHfhyk;  
(Ig;grp-fhHj;jpif) 
( Oct 15 – Dec 15) 
,sNtdpy; 
(rpj;jpiu - itfhrp) 
( Apr 15 –June 15) 
 
 
 
 
jd;dpiy 
milj;jy; 
$jpHfhyk; (Ig;grp - 
fhHj;jpif) 
( Oct 15 – Dec 15) 
Kd;gdp  
(khHfop - ij) 
( Dec 15 – Feb 15) 
KJNtdpy;  
(Mdp - Mb) 
(June 15 – Aug 15) 
 
cjputhj RNuhzpjk;  kUj;Jt Ma;tpy; fhHfhyk;> $jpH fhyk;> 
KJNtdpy; fhyk; ,tw;wpy; Nehahspiaf; fhz Kbe;jJ.  
vz;tifj; NjHTfs;: 
 Kw;$wpa gpzpia mwpAk; top> kUj;Jt E}y; ty;NyhHfshy; vz; 
tifaha; cUthf;fg;gl;Ls;sJ.  
 ‘ehbg;ghprk; ehepwk; nkhoptpop 
  kyk; %j;jpukpit kUj;JtuhAjk;” 
1. eh  2. epwk;  3. tpop  4. nkhop 
5. kyk; 6. %j;jpuk;  7. CW  8. ehb 
 ‘nka;f;Fwp epwe;njhzp tpopehtpUkyk; iff;Fwp”    
     - NjiuaH 
t. 
vz;. 
vz; tif 
NjHTfs; 
cjputhj RNuhzpj 
Nehapy; fz;lJ 
Extra – Articular 
1.  eh 
Ritapd;ik / cg;Gr; 
Rit> ehtwl;rp> 
ntbg;Gfs; 
Pallor of tongue, 
Tastelessness / salt 
taste Dryness of 
salivary secretion 
2.  epwk; 
ghjpf;fg;gl;l %l;by; 
rpte;jpUj;jy;> kpDkpDg;G 
fhzg;gl;lJ 
Livedo Recticlaris (+) 
In Synovitis – the 
inflamed joint is red 
and swollen. 
3.  tpop ntSj;Jf; fhzg;gl;lJ 
Episcleritis, corneal 
ulcer, Retinitis, 
cataract, scleromalacia 
perforans. 
  
 
 
 
 
 
 
4.  nkhop kpjkhd xyp - 
5.  ];ghprk; 
tPf;fKs;s%l;Lfspy; 
ntg;gk; czug;gl;lJ 
- 
6.  kyk; kyr;rpf;fy; fhzg;gl;lJ - 
7.  rpWePH ,skQ;rs;/ gbfepwk; - 
8.  ehb thjehb - 
 
rpWePH:  
 ,Utifahd rpWePH ghpNrhjidfs; cs;sd. 
1. ePHf;Fwp 
2. nea;f;Fwp 
1. ePHf;Fwp 
 ‘mUe;Jkhwp ujKk; mtpNuhjkjha; 
  M/fy; myHjy; mfhyT+d; jtpHe;jow;   
 Fw;wstUe;jp cwq;fp itfiw                        
Mbf; fyrj; jhtpNa   fhJnga; 
  njhUK$Hj;jf; fiyf;fl;gL ePhpd; 
  epwf;Fwp nea;f;Fwp epkUj;jy; flNd” 
- mfj;jpaH ehb    
 
muntd ePz;bd..;Nj thjk; 
MopNghw; gutpd; m..;Nj gpj;jk; 
Kj;njhj;J epw;fpd; nkhopt njd; fgNk 
mutpy; MopAk; Mopapy; muTk; 
mutpd; Kj;Jk; Mopapy; Kj;Jk; 
 
 
 
 
 
cz;Zfpd;w mWRitg; nghUs;fSk; xd;Wf;nfhd;W 
Ntw;WikailahkYk;> grpf;Fj; jf;fgb Fiwjy;> mjpfhpj;jy;> 
fhye;jg;Gjy; Kjypa Fw;wq;fSz;lhfh tz;zk; Grpj;J cwq;fp> 
tpbaw;fhyj;jpy; gbf ghj;jpuj;jpy; ePiu Mtp Nghfhjgb nra;j 3¾ 
ehopiff;Fs; mjd; epwf;FwpiaAk;> mjpy; vz;nza; tpl;Lg; ghHj;J 
fhzg;gLfpd;w FwpiaAk; ftdpj;J gpzpfspd; jPUk;> jPuhj Fwpfis 
nka;g;gpj;jy; KiwahFk;. 
‘te;j ePHf;fhp vil kzk; Eiu vQ;rnyd; 
 iwe;jpaYsit aiwFJ KiwNa” 
vd NjiuaH $wpagb  
 epwk; 
 Eiu 
 kzk; 
 vQ;ry; 
 vil 
cjputhjRNuhzpjj;jpy; ePHf;FwpahdJ ,skQ;rs; / gbf epwj;jpy; 
fhzg;gl;lJ. 
 
2. nea;f;Fwp: 
 ‘epwf;Fwpf; Fiuj;j epUkhz ePhpw; 
  rpwf;f ntz;nza;NahH rpWJsp eLtpLj; 
  njd;Wwj; jpwe;njhyp Vfh jikj;jjp 
  dpd;wjptiy Nghk; newptpop awpAk;  
  nrd;wJ GfYQ; nra;jpia azNu” 
- NjiuaH 
ePH epwf;Fwpahy; Nehiaf; fz;Lgpbj;jw; nghUl;Lr; 
nrhy;ypapUf;fpd;w tpjp nghUe;jpa rpWePhpy; xU rpwpa Jsp vz;nza;ia 
eLtpy; iftpirapdhy; vz;nza; Jsp rpjwhky; tpl;L nta;apyhdJ 
me;ePhpy; gLk;gb jpwe;J> fhw;whdJ mjpy; tPrp> me;j vz;nza; Jsp 
Mlhjgb itj;J> mr;rpWePhpy; tplg;gl;bUf;fpd;w vz;nza; JspahdJ 
 
 
 
 
nry;Yfpd;w topapy; fz;zwpitAk;> capuwpitAk; nrYj;jp> mj;Jsp 
njhptpf;Fk; Neha; tpsf;fj;ij njhpe;J nfhs;s Ntz;Lk;. 
nea;f;Fwp ngUk;ghYk; Kj;J xj;J ,Ue;jJ. rpyUf;F thjePH Nghy 
nfhk;Gfs; ePz;L fiye;jJ. 
nea;f;Fwp: 
t. 
vz; 
nea;f;Fwp 
NehaHfspd; 
vz;zpf;if 
% 
1. ry;yilf;fz; 1 3 
2. Kj;J 36 90 
3. nfhk;Gfs; Nghy ePz;lJ 3 7 
 
cly; td;ik: 
cly; td;ik %d;W tifg;gLk;. 
1. ,aw;if td;ik - Natural Strength 
2. fhy td;ik  - Seasonal Strength 
3. nraw;if td;ik - Artificial Strength. czT kw;Wk;  
gof;ftof;fq;fshy; jUtpg;gJ. 
cjputhj RNuhzpjk;  ,aw;if kw;Wk; nraw;if td;ik ghjpf;fg;gLk;. 
Neha; epjhdk;:- 
 ‘A+fp itj;jpa rpe;jhkzp” E}ypy; 80 thjq;fspy; %l;Lfspy; tUk; 
tpahjpfisg; gw;wp rpy thjq;fspy; $wg;gl;Ls;sJ. 
1. fhshQ;rfthjk; 
2. re;J thjk; 
3. ehpj;jiy thjk; 
4. kiyj;jfk;g thjk; 
5. igj;jpa thjRNuhzpjk; 
6. thjRNuhzpjk; 
1. fhshQ;rf thjk;: 
 ‘khjkq; fhy;ifapy; Fwq;fp uz;Lk; 
   tUj;Jre;J KWf;fpNa File;J nehe;J 
  ehjkh eiljhDq; jhd;nfh lhky; 
  eype;JNk Klkhfpf; fuL fl;b  
 
 
 
 
  NrjkhQ; rle;jhD kpfnt Sj;Jj; 
  jpdNthL rpuq;Fkha;r; Nrl;g khfpf; 
  fhjkh aUrpnahL kaf;f khFk; 
  fUjpa fhshQ;rf tspap jhNk” 
 if> fhy;> njhil> %l;L mitfspy; gpsg;gJ Nghd;Wk;> FiltJ 
Nghd;Wk;> nehe;J> elf;fnthl;lhkw; nra;Ak;.  
 cly; nkype;jpUf;Fk;. 
 re;Jfs; NjhWk; Klq;fp> fuL fl;bf; nfhs;Sk;. 
 cly; kpf ntSj;Jj; jpdntLj;Jr; nrhwp rpuq;Fz;lhFk;. 
 Iak; $b> Ritapd;ik> kaf;fk; Kjypa cz;lhFk;. 
 
2. re;Jthjk;:- 
 ‘nra;ifjhd; re;JfS kpfj;jp kpHe;J 
  rlnkq;Fk; nehe;JNk kpft ow;wp 
  eifaha; eSj;JNk kapHf;fTr; rpl;L 
  ez;zpNa Kd;Nghy elf;nfhl; lhJ 
  ikifjhd; kaf;fnkhL tha;eP &Wk; 
  twz;bLNk ehTe;jhd; mbf;f bf;F 
  ijifjhd; juzpjdpy; jhpf;nfh zhJ 
  rrypf;FQ; re;Jfspd; tspf shNk”. 
 fPy;fs; NjhWk; epkpHe;J clnyq;Fk; nehe;J kpFe;j mow;rp 
cz;lhFk;. 
 kapHf;$r;nrwpAk;. 
 elf;f Kbahik> kaf;fk;. 
 tha; eP&wy;> ehtwl;rp. 
 fhy;fs; epyj;jpy; itf;f KbahjthW Jd;GWj;jy;. 
3. ehpj;jiy thjk;:- 
 ‘%Hf;fkha; Kad;W Koq; fhy;jhd; tPq;fp 
   KjpHe;Juj;j Ke;jpuz;LKaw;rpahfp 
  ePf;fkha; epd;wplnth zhkw; whDk; 
  epkpHe;jpLfpy; re;Je;jhd; Klf; nfhzhky; 
  jPHf;fkha;j; Jz;bj;J kpfr; rpf;nfd;W 
  nrOikehpj; jiyNghy kpfNt tPq;fp 
  ehHf;fkha; ehbANk glg lf;Fk; 
 
 
 
 
  ehpj;jiyapd; thjnkd;Nw etpy yhNk” 
 Koq;fhy; %l;by; nre;ePH epuk;gp> rpte;J> tPq;fpapUf;Fk;. 
 %l;bid ePl;lTk;> klf;fTk; Kbahky; ehpapd; jiyiag; Nghy; 
kpFjpAk; tPq;fpf; fhZk;. 
4. kiyj;jfk;g thjk;:- 
 ‘Fk;gkhq; ifapd; kzpf;fl;L jd;dpy;  
  Ftpe;jiuapw; nkhrif NghY uj;Jf; fhZk; 
  Jk;gkk; mq;fq;fs; Jbg;g jhFk; 
  Jz;LNk fhy; ifA eLf;f khFk; 
  mk;ghkk; miuf;Fq;fPo; jpkpUz; lhFk; 
  mjuNk kpff;fWj;J ntbg;Gz; lhFk; 
  tk;gkhk; thAjhd; ghpa ehw;wk; 
  tUkiyj;j fk;gj;jpd; khHf;f khNk”. 
 ifapd; kzpf;fl;Lg; G+l;Lfspy; tPq;fpj; jbj;Jf; fhZk;. 
 cly; Jbf;Fk;> iffhy; eLq;Fk;. 
 miuf;Ff; fPo; jpkpUz;lhFk;. 
 cjL kpff; fUj;J ntbg;Gz;lhFk;. 
 kpf;f ehw;wj;Jld; fhw;Wg; gphpAk;. 
 
5. igj;jpathjRNuhzpjk;: 
 ‘czHr;rpahr; RNuhzpje;jhd; kpfnt Jk;gp 
  Cf;fkha;j; Njfnkq;F kpfNt nehe;J 
  KzHr;rpaha; Koq;fhy;fs; Koq;if nahf;f 
  Kidahd rpWtpuy; fd;dk; new;wp 
 jzHr;rpaha;r; re;J rU thq;f nkq;Fk; 
  jhl;Bf kha;f;File;J Ru Kz;lhk; 
 gzHr;rpaha;g; ghz;lJNghd; Nkdp ahFk; 
  igapj;jpathj RNuhzpjj;jpd; gz;G jhNd”. 
 
 clypy; cs;s FUjp> gpj;jthjf; Fw;wg; ngUf;fhy; kpf;f nfhjpj;J> 
cly; KOikAk; gha;e;J> Nehfr; nra;Ak;. 
 
 
 
 
 Koq;fhy;> Koq;if> rpWtpuy;fs;> fd;dk;> new;wp Kjypaitfs; 
NrhHe;J> vy;yh cWg;GfSk; Nehfr; nra;Ak;. 
 Ruj;ijAk;> ghz;L> Nrhig NehiaAk;> gapj;jpaj;ijAk; gpwg;gpf;Fk;. 
 
6. thj RNuhzpjk;: 
 ‘mwpe;jpl;l tq;fnkyhk; nkypT khfp 
  mirthd jt;tplq;fs; tPf;f khfp 
  ewpe;jpl;l eilnfhlh jhap Uj;jy; 
  eypahfp KbKbaha; tPf;f khfr; 
  nrhwpe;jpl;l clk;ngq;F kirT fhzy; 
  Nrhw;wpd;Nk dpid tpd;wpj; J}f;f khjy; 
  twpe;jpl;l thajdpy; ePHjh D}wy; 
  thjR Nuhzpje;jhDk; tFj;j thNw”. 
 
 cly; nkype;J miraf; $ba %l;Lfspy; tPf;fk; cz;L gz;Zk;. 
 elf;f Kbahky; gLf;ifapy; gLf;fr; nra;Ak;. 
 Neha; Kjpu Kjpu tPf;fk; kpFk;. 
 cly; eLf;fk;> cztpy; epidtpd;wp kpf;f J}f;fj;ij tUtpj;jy;. 
 thapy; ePH Cwpf; nfhz;Nl ,Uj;jy; Mfpa FwpFzq;fs; thj 
RNuhzpjj;jpy; Njhd;Wk;. 
 
gj;jpak; 
 kUe;J jpd;wpbd; gj;jpak; 
  tFj;jplh tpbDk; 
 mUe;j thfplhg; nghUs;fis 
  mfw;wNt Ntz;Lk; 
 nghUe;jplhJ ngz; NghfNkhH 
  kUe;Jf;Fk; Gtpapy; 
 tUe;j NthUl ywpe;Jgj; 
  jpae;jid tFg;gha;” 
 
 ‘gj;jpaq; nfhz;l NgHfs; 
  gfw;Wapy; nfhz;l fhiyr;  
 epj;jpu ghD ntg;gQ; 
 
 
 
 
  nrg;gpL kUe;jpd; ntg;gk; 
 gj;jpar; nraypd; ntg;gk; 
  gfUepj; jpiuapd; ntg;gk; 
 ,j;jid ntg;gq; $b 
  dpaYNeha;f; fstpd; nwd;Nd” 
kUe;J cz;Zk; fhyq;fspy; gfy; cwf;fk; $lhJ. mg;gb 
J}q;fpdhy; J}f;fj;jpdhy; Vw;gLk; ntg;gk;> #hpa ntg;gk;> kUe;jpd 
ntg;gk;> gj;jpaj;jpd; ntg;gk; ,t;tsTk; clypy; NrHe;J mstpwe;j 
Neha;fs; cliyaZFk;. 
Mfhj nghUl;fs;: 
 ‘fLF ww;wpyj; njz;nza; $o;g;ghz;lq;fs; fliy 
  tLt jhfpa njq;Fkh tUf;if ew;fhak; 
  kbtp yhjnts; Ss;spnfhs; Gifapiy kJngz; 
  ,lW ghfNyh lfj;jp ePf;fplypr; rhgj;jpak;” 
fLF> ey;nyz;nza;> G+rzp> fs;> fliy> Njq;fha;> khq;fha;> gyh> 
fhak;> cs;spg;G+z;L> nfhs;> Gifapiy> ngz;fs; NrHf;if> ghfy;> mfj;jp 
Mfpatw;iw ePf;f Ntz;Lk;. 
MFk; nghUl;fs;: 
 ‘fLik nad;wpL gj;jpa 
  KtHtWj; Jz;ly; 
  miltp yhkW gj;jpaj;  
  JtH tWj; jUj;jy; 
  nfhLik nra;Gsp jidr; Rl;Lf; 
  $l;bl yd;wpg; 
  gbapy; fj;jhp rpf;Fug; 
  gpQ;rpidg; gUfy;! 
tWj;j cg;G> Rl;lGsp> fj;jhp> KUq;ifg; gpQ;R Mfpait MFk; 
nghUl;fs;. 
  
 
 
 
 
MANAGEMENT 
 Ie;jpuj;jhy; (Ik;G+j jj;Jtk;) cUthdNj mz;lKk;> gpz;lKk;> 
Ie;jpuj;jpy; Vw;gLk; Vw;wj;jho;TfNs Nehia cUthf;FfpwJ. 
gQ;rG+jgQ;rPfuzg; gb Ie;J G+j jj;Jtq;fspd; NrHf;ifahy; cWg;GfSk;> 
jputq;fSk;> njhopy;fSk;> nray;fSk;> czHTfSk; cUthfpwJ. 
gQ;rG+jgQ;rPfuzj;jpy; Vw;gLk; Vw;wj;jho;Tfs; Neha;fis 
Njhw;Wtpf;fpwJ. vdNt ,e;j gQ;rG+jgQ;rPfuzj;jpid rPHgLj;j> 
Kjy; ehs; 
 fhw;Wj;jj;Jtj;ij mbg;gilahff; nfhz;l nka;ia rPH nra;a 
Kjy; ehs; ijy Fspay; nra;a mwpTWj;jg;gl;lJ. FspaYf;F thj 
Neha;fisf; Fzg;gLj;Jk; Ntq;ifg;gl;ilj;ijyk; nfhLf;fg;gl;lJ.  
,uz;lhtJ ehs; 
 rpj;jHfspd; ngaHfis Kjd;ikahff; nfhz;l rpj;jhjp vz;nza; 
kUe;J toq;fg;gl;lJ. 
 rpj;jhjp vz;nza; - 10 kp.yp. 
mjpfhiyapy; ntWk; tapw;wpy; ePuhfhuj;jpy; toq;fg;gl;lJ. 
mLj;jehs; Xa;T nfhLf;fg;gl;lJ. 
4 tJ ehs;Kjy; 
 kapypwfhjp vz;nza; - 4 kpyp 
 ,Q;rp rhW kw;Wk; Njd; fye;J ,U Ntis nfhLf;fg;gl;lJ.  
 
kapypwfhjp vz;nza; cl;nfhs;Sk; Kiw:- 
 Ie;J ehl;fs; kUe;J cz;l gpwF %d;W ehl;fs; ,ilntsp tpl 
Ntz;Lk;. gpwF kPz;Lk; Ie;J ehl;fs; kUe;J cl;nfhs;s Ntz;Lk;. ,g;gb 
40 ehl;fs; kUe;J cl;nfhs;s Ntz;Lk;. 
Gw kUj;Jtk; 
 xw;wlk; - vd;G G+l;Lfspy; cs;s tPf;fk;> typ Mfpatw;iw Fzkhf;f 
mtw;wpd; kPJ xw;wlkplyhk;. cjputhjRNuhzpjNehapy; 
NehaHfSf;F kQ;rzj;jp ,iy kw;Wk; Mkzf;F tpij xw;wlk; 
mspf;fg;gl;lJ. 
 cjputhj RNuhzpj NehaHfSf;F mwpTWj;jg;gl;l Kj;jpiufs; 
thA Kj;jpiu - tspia rkepiyg;gLj;Jk; 
 
 
 
 
Rugp Kj;jpiu - cjputhjRNuhzpjNehia Fzkhf;Fk;. 
,ypq;f Kj;jpiu - Neha; vjpHg;G rf;jpia $l;Lk;. 
gpuhz Kj;jpiu - gpuhziz rkepiyg;gLj;Jk;.  
Neha;fSf;F Kjw;fhuzkhd 
%yhjhur;rf;fuj;ij tYg;gLj;Jk;;. 
 toq;fg;gl;l rpwg;G kUj;Jt Kiwfs;: 
- njhf;fzk; 
- tHkk; 
- jpahdk; 
- gpuhzhahkk; 
- Kj;jpiu  
 clw;gapw;rpfs; 
- fOj;J Row;rp 
- Njhs;gl;il> kzpf;fl;L Row;rp 
- fhy; Row;rp 
- cly; jpUF gapw;rp 
 
Fwpg;G 
 Kjy; ehs; kUj;Jtk;: 
40 cjputhjRNuhzpjNehaHfSf;Fk;> Kjy; ehs; kUj;Jtkhf  
Ntq;ifg;gl;ilj; ijyk; Nja;j;J Fspg;gjw;F toq;fg;gl;lJ. mtHfsplk; 
fhzg;gl;l khw;wq;fs;.  
 clypYk;> kdjpYk; Gj;JzHT Vw;gl;lJ. 
 J}f;fkpd;ik ePq;fp ey;y cwf;fk; cz;lhdJ. 
 kdmikjp cz;lhdJ. 
 cly; NyrhdJ Nghd;w czHT Vw;gl;lJ. 
 mjpfkhd grpAk;> Kidg;G jd;ik fhzg;gl;lJ. 
Fwpg;G 
nka; - fhw;W G+j (thjk;) $WghL cilaJ 
fhw;W + Mfhak; = tsp. tsp Fw;wj;ijj; jd;dpiyg;gLj;J ijyf; 
Fspay; mtrpak;. 
 
 
 
 
 ,uz;lhk; ehs; kUj;Jtk;: 
rpj;jhjp vz;nza;  
 rpj;jhjp vz;nza; Ngjp kUe;J kl;Lky;y. clypd; ,aq;F 
#l;ilAk;> clypy; jq;Fk; caphpd; #l;ilAk; rkepiyapy; ,Uf;fr; nra;Ak; 
kh kUe;J. ehbia Rj;jp nra;Ak; mtpo;jk;. 
rpj;jhjp vz;nzapd; gjk;.  
‘mg;gNd njhl;Lg;ghU Rj;j ryk; NghyhFk;...” 
nfhjpj;J nfhz;bUf;Fk; rpj;jhjp vz;nza; gjk; tUk; NghJ 
ifia tpl;L ghHj;jhy; jz;zPiu njhLtJ Nghy ,Uf;Fk;.  
mrhj;jpankd;W fUjg;gl;l Neha;fshf ,Ug;gJk; FzkhtJ 
jpz;zk;. 
cjputhjRNuhzpjk; gw;wpa ,e;j ma;Tf;fl;Liuapy; 40 cjpu 
thjRNuhzpj NehaHfSf;Fk; ,uz;lhk; ehs; rpj;jhjp vz;nza; 
toq;fg;gl;lJ.  
 ehl;gl;l cjputhjRNuhzpj NehaHfSf;Fk;> typ kw;Wk; Nehapd; 
jd;ik jPtpukhf cs;stHfSf;Fk; njhlHe;J 3 ehl;fs; Ngjp kUe;J xU 
gphptpdUf;Fk;> 15 ehl;fSf;F xU Kiw Ngjp kUe;J kw;nwhU 
gphptpdUf;Fk; toq;fg;gl;lJ. 
Sl.No. Stages 
No. of 
Patients 
No. of days Results 
1.  
Severe pain & stiffness in 
Joints 
20 
3 days (or) 
once in 15 days Good 
2.  Moderate Pain 10 1 Good 
3.  Diseased 10 1 Good 
 
cjputhjRNuhzpj Nehahspapd; clypy; ghjpf;fg;gl;l Kf;Fw;wk;.> Ik;G+jk;> 
VO clw;fl;Lfs; Mfpa %d;W KOKjw;fhuzpfisAk; rpj;jhjp 
vz;nza; Fzg;gLj;JfpwJ.  
 
 
 
 
 
 
 
Benefits: 
 After the action of the medicine, all the Uthiravathasuronitham patients (ie) 
100% of them were relieved from severe joint pain, and morning stiffness. They 
fell on a sound sleep. Good appetite is generated. They feel a sense of freshness, 
and spirit. The periodical episodes of pain and fever is also very well controlled 
and reduced.    
 
rpwg;G kUj;Jtk; 
1. njhf;fzk; (kHj;jdk;) 
 njhf;fzj;jpid ‘kHj;jdk;” vd;Wk; $wyhk;. ,J thjj;jhy; 
cz;lhFk; vy;yh Neha;fisAk; ePf;Ftjpy; rpwg;GilaJ. 
    
    ‘njhf;fzj;jp dhypuj;je; Njhy; Y}dpitfl;F 
 kpf;f rTf;fpaQ;r kPuDk;Ngh - nka;f;fjpf 
 Gl;bAwf;fk; GzHr;rp apit fjpf;Fk; 
 gl;l miyr;ryWk; ghH” 
- Njud; - jU. 
 
njhf;fzk; nra;Kiw xd;gJ tifg;gLk;. 
jl;ly; (Stroking), ,Wf;fy; (Clinching), gpbj;jy; (Kneding), KWf;fy; 
(Twisting), fl;ly; (Locking), mOj;jy; (Pressing), ,Oj;jy; (Pulling)> 
ky;yhj;Jjy; (Stretching), mirj;jy; (Shaking). 
cjputhjRNuhzpjj;jpy; njhf;fz Kiwfspy; gpbj;jy;> fl;Ljy;> 
,Wf;fy; Mfpa %d;W epiyfisf; ifahsyhk;.  
 
 Nehapd; jPtpu epiyapy; njhf;fzk; nra;tJ jtpHf;fg;gLfpwJ. KO 
Xa;T kl;Lk; mwpTWj;jg;gLfpwJ.  
 Nehapd; jPtpuk; Fiwe;j epiyapy; gpbj;jy; Kiwapy; kpf ,Nyrhf 
njhf;fzk; nra;a ed;ik gaf;Fk;. 
 
 
 
 
 
 
Massage 
1. Massage is strongly encouraged by the American Arthritis Foundation for 
the sub – acute phases of RA, though discouraged in the acute phase, as 
massage increases circulation and may increase the chance that the disease 
in this phase may spread. 
2. Massage is beneficial in reducing the effects of RA on joints and range of 
motion but beneficial in keeping the joints supple and mobile. 
3. It also promote the mobility and health of the soft tissues around the joints.  
4. Massage for pain control 
a. Massage confuses the body’s pain signal. 
b. It stimulates the release of endorphin the body’s natural pain killers. 
It relieves muscle tension, spasm and stiffness, and also mental stress and 
anxiety. Massage improves blood circulation, bringing with it oxygen and other 
forms of nourishment. The muscle then relaxes, and pain decreases. It is contra – 
indicated in inflammation. 
2. tHkk;: 
cjputhjRNuhzpj Nehapy; tHk jlty; Neha; epiyia mjpfhpf;Fk;. 
mjdhy; tHk mlq;fy;fspy; jlty; Nkw;nfhs;sg;gLfpwJ.  
v.fh. mfjhiu> Gwjhiu> cs;sq;if nts;is mlq;fy;> if klf;F 
mlq;fy;> fhy; klf;F mlq;fy;. 
3. xw;wlk; (Fomentation):  
 thj Neha;fspy; xw;wlk; kpf;f ed;ik GhpfpwJ. 
 jOjhio (thjklf;fp)> thjehuhazd;> nehr;rp> Mkzf;F> gpukp> 
MlhNjhil Nghd;w %ypiffspy; VNjDk; xd;wpd; ,iyfis rpWf 
mhpe;J vz;nzapy; tjf;fp Jzpapy; Kbe;J> ghjpf;fg;gl;l %l;Lfspy; 
xw;wlkplyhk;.  
xw;wlj;jpd; tiffs; 
gad;ngw;w Nehahspfspd; 
rjtpfpjk; 
kQ;rzj;jp ,iy 35% 
Mkzf;F tpij 65% 
Mjhuk; : rpj;jH mWit kUj;Jtk; 
 
 
 
 
 cjputhjRNuhzpj Nehapy; ghjpf;fg;gl;l %l;Lfspy; mjpf typAk; 
tPf;fKk; cs;sjhy; ePz;l Neuk; xw;wlk; nfhLf;f Ntz;bAs;sJ. mjdhy; 
cjputhjRNuhzpjNehahpy; typiaAk; tPf;fj;ijAk; Fiwf;Fk; nghUl;L 
mjpf #l;ilj; juf;$ba Mkzf;F tpij xw;wlk; kpFe;j gyd; 
mspj;Js;sJ. 
 
Benefits of Fomentation 
• The external heat produced by the Otradam (xw;wlk;) increases the 
vascularity around the affected joints and facilitates the venous return and 
lymphatic drainage.  
• Reduces the swelling of joints.  
• Reduces the inflammation. 
• Produces the flexibility of muscles around the joints. 
• Reduces the stiffness of joints. 
• It facilitates the range of movements of the affected joints. 
 
gpuhzhahkk;> Mrdk;> Kj;jpiu> jpahdk; Mfpa ehd;F KiwfSk; 
kdpj jj;Jtj;ij gpugQ;rrf;jpNahL ,izf;Fk; jd;ik tha;e;jJ. 
,g;gapw;rpfis gofp tu kdpjdpd; gUcly; kl;Lky;y Ez;Zly; 
kw;Wk; fhuzclypy; Vw;gLk; Fw;wq;fs; ePq;fp epiwtho;T ngwyhk;. 
4. Mrdq;fs; (Yoga Asanas): 
Mrdq;fs; ml;lhq;fNahfj;jpy; %d;whtJ gbepiyahFk;. 
cjputhjRNuhzpjj;jpy; nghJthf Nkw;nfhs;sg;gLk; Mrdq;fs; 
fbdkpd;wp ,Uj;jy; Ntz;Lk;.  
• Neha; epiyikf;F Vw;g Muk;g epiyapy; 
cl;fl;lhrdk;>gtsKj;jhrdk;>Rfhrdk;>mHj;jgj;khrdk;> 
jlhrdk; Nghd;w Mrdq;fs; nra;ayhk;. 
• Nehapd; jPtpu epiyapy; rhe;jp Mrdk; nra;a ey;y gyd; fpilf;Fk;. 
clYk; kdKk; Gj;Jzh;T ngWk;. 
 
 
 
 
 
 
gad;: 
• cjputhjRNuhzpjj;jpy; Vw;gl;l kdrQ;ryk; ePq;Fk;. 
• cly; fisg;igg; Nghf;Fk;. 
 
5. Kj;jpiufs; (Mutthirai): 
Mudra means gesture symbol or seal. It is characterized by muscular 
contraction and relaxation or manipulation of Internal pressure devised for starting 
off stimulating temporarily some specific parts of the body. Regular practice of 
mudra will help to control the involuntary organs and muscles which are connected 
with nerve or channels which conduct the life force throughout the body. Benefits 
could be derived more quickly from mudras than from asanas. It is more 
effective if it is carried out in both hands.  
A. Prana Mutthirai:  
Procedure: 
Touch together lightly the tip of the thumb, with the ring finger and little 
finger. These three fingers makes vital energy (prana)start to flow and rejuvenate 
the whole body. 
By practising Prana mutthirai Uthiravathasuronitham patients gained 
general health to some extent.  
B. Vayu Mutthirai 
Procedure:  
 The index finger lightly touches and presses the base of the thumb. The 
thumb curls over and lightly presses the knuckle of the index finger.  
By practising vayu mudra, Uthiravathasuronitham patients joint pain and 
vaatha characters decreased.  
C. Surabi Mutthirai 
 Touch the tip of all the fingers of Right hand with the fingers of the left 
hand in an alternate way.  
    Right      Left 
 Thumb Finger with  Thumb Finger  
 Index Finger with  Middle Finger 
 
 
 
 
 Middle Finger with  Index Finger 
 Ring Finger  with   Little Finger 
 Little  Finger with   Ring Finger 
This mutthirai is very specific for Uthira vatha suronitham, for it reduces 
the joint pain and morning stiffness. Changes in Vatha symptoms is also noted.  
D. Linga Mutthirai:  
 Tightly close both the hands together and place right thumb finger stand in 
an erect manner.  
 In Uthiravathasuronitham joint pain and disease severity increases on 
exposure to cold weather. By practising Linga Mutthirai Uthira vatha suronitham 
patients generated heat in their body. By this they were able to overcome the 
demerits of cold weather.  
6. gpuhzhahkk;: 
 ml;lhq;fNahfj;jpy; xd;whd gpuhzhahkk; vd;gJ Rthrg; 
gapw;rpahFk;. 
 fw;g Kiwfspy; xd;W  
 ‘Vw;wp ,wf;fp ,UfhYk; G+hpf;Fk; 
  fhw;iw gpbf;Fk; fzf;fwp thhpy;iy 
  fhw;iw gpbf;Fk; fzf;fwp thsHf;F 
  $w;iw cijf;Fk; FwpaJ thNk”  
- jpUke;jpuk; 
 ,g;gapw;rpapdhy; euk;G kz;lyq;fs; gyg;gLfpd;wd> rpj;jk; trg;gLk;. 
 gpuhzhahkj;jpd; clypaq;fpay; ed;ikfs; 
 xU Rthrj;jpd; nkhj;j fhw;wpy; 3y; 2 gq;F thA ghpkhw;wj;jpy; 
gq;nfLg;gij (Alveolar Ventilation) jtpu tPzhFk; 3 - y; 1 gq;F (Airway 
ventilation) fhw;iwAk;> thA ghpkhw;wj;jpy; gq;nfLf;f itf;f gpuhzhahkk; 
gad;gLfpwJ. 
 Rthrg;gapw;rpapd; %yk; gpuhzd; clypy; Nru Nru Nehapd; 
jd;ikfs; Fiwe;J eyk; cz;lhFk;.  
 
 
 
 
 
 
 kUj;Jtg; gad;fs;:  
 cjputhjRNuhzpjj;jpy; ghjpg;gile;j tsp> moy;> Iak; %d;iwAk; 
rkg;gLj;j gpuhzhahkk; cjTfpwJ. mjdhy; clypd; jl;gntg;gk; 
rkepiyapy; itf;fg;gLfpd;wJ. 
7. jpahdk;:- 
 m\;lhq;f Nahfj;jpy; xd;whd jpahdj;ij goFtjhy; clypd; 
Mw;wy; ikaq;fshf mike;Js;s MW Mjhuq;fSk; jd; epiyapy; 
,Uf;Fk;. mg;NghJ clypy; gpzp Vw;glhJ. ,jd; rkepiy jtWk; gl;rj;jpy; 
mtutUf;Fj; jf;fthW cly; cghijfs; Njhd;Wk;. mJ kl;Lkpd;wp Neha; 
tuhkYk; jLf;fyhk;. cjputhjRNuhzpjj;jpy; ngUk;ghyhd Nehahspfspy; 
fhzg;gLk; Mjhuq;fspd; khWgl;l epiyfis jpahdg; gapw;rp %yk; rPH 
nra;ayhk;. 
 ,tHfSf;F jpahdg; gapw;rp %yk; ek;gpf;ifAk; (Confidence), 
Gj;JzHr;rpAk; (Refreshment) fpilf;fpd;wJ. 
clypaq;fpay; ed;ikfs;: 
• jpahdj;jpd; NghJ nruNlhdpd; (Seratonin) Rug;G mjpfkhtjhy; 
kdj;njspTk;. vz;lhHgpd; (Endorphin) vd;nrgypd; (Encephalin) 
Nghd;w Rug;Gfs; mjpfkhtjhy; typfspypUe;J epthuzKk; 
fpilf;fpwJ. 
During anxiety and tension states there is a rise in the level of lactate in the 
blood. Lactate production in the body is mainly in skeletal muscle tissue. During 
meditation the faster circulation brings a faster delivery of oxygen to the muscles 
and less lactate is produced.  
8. NtJ 
    ‘ePHKfj;j Oe;jptr ahYise;J lk;GjsH 
  thjidf;f lq;ftL NtJitg;g Oq;fyw  
  epjkl;l GdYl;l zkpUf;f ytzj;ij 
  ajpypl;L Kjkpl;L ldpUf;f NtHj;jpLk; 
  Nkdpapw;ngh Ue;JespH thjkpf;f tq;fKid 
 thFkpf;f ze;jzyp Nynahpf;f ntk;GKly;  
 tpaHTw;W eypaw;W yFkpf;f kpJepr;ra 
 
 
 
 
  epUkpj;j gplfHf;f tjpapl;l tha;g;gpJ - Gw  
  nkypTkPJ gw;WNs FNk”.   
        - Njud; jU 
cly; typ> jpus;thA Mfpa ,tw;wpw;Ff; nfhjpf;Fk; ePiu xU 
thafd;w ghj;jpuj;jpY}w;wp> mjpy; cg;Gg; nghbia epuk;gg;Nghl;L 
mjdpd;nwOk; Mtpia clypy; gLkhW nra;ayhk;. ,g;gbr; nra;tjhy; 
tpaHit Az;lhfp Ntjid jzpAk;.  
Steam Bath 
 It rises the body temperature without causing overheat, while the mist 
vapours circulate creating 100% humidity. 
 The benefits of a steam bath are numerous. In Uthiravathasuronitham 
patients, steam bath induced the following benefits.  
• Increased circulation for healthier skin felt more energetic. 
• Relaxed the stiff muscles & eased the swelling or tension in the joints 
affected.   
  
 
 
 
 
RHEUMATOID ARTHRITIS 
 
 The term rheumatoid arthritis was first used by Sir Archibald 
Garrod in 1876 to describe a chronic non-suppurative inflammatory 
arthropathy distinct from gout and osteoarthritis. It is generally regarded 
as an auto-immune disease but details of its pathogenesis remain 
unclear. Its prevalence is remarkably consistent worldwide 
(approximately 1 per cent) with a few important exceptions that have 
helped to highlight environmental influences and the role of the immune 
response genes. Inflammation of the synovial joints leading to 
destruction of joints and peri articular tissues is, the most obvious 
clinical and pathological characteristic of the disease, but a wide variety 
of extra-articular features can also develop. 
 Rheumatoid Arthritis is a chronic multisystem disease affecting 
the connective tissues of the whole body with focalised involvement of 
the musculoskeletal system. The characteristic feature of established RA 
is persistent inflammatory synovitis usually involving peripheral joints 
in a systemic distribution. The potential of Synovial inflammation to 
cause cartilage damage, bone erosions and subsequent changes in joint 
integrity is the hallmark of the disease. The course is variable despite of 
destructive potential. Some patients experience a mild oligo articular 
illness of brief duration with minimal joint damage but most will have 
progressive polyarthritis with marked functional impairment clinical 
manifestations. 
 RA is a chronic polyarthritis. In approximately 2/3 of patients it 
begins insidiously with Fatigue, Anorexia, generalized weakness, vague 
musculoskeletal symptoms until the appearance of synovitis becomes 
apparent. 
 Specific symptoms usually appear gradually as several joints, 
especially those of hands, wrist, knee and feet become affected in a 
 
 
 
 
symmetric fashion. In some of individuals  constitutional symptoms, 
including fever, Lymphadenopathy, Spleenomegaly are present. 
Epidemology 
 The incidence og RA is in the region of 3 cases per 10,000 
population per annum. Onset is uncommon under the age of 15 and from 
then on the incidence rises with age until the age of 80. The prevalence 
rate is 1%, with women affected three to five times as often as men. 
First – degree relatives prevalence rate is 2 – 3 % and disease genetic 
concordance in monozygotic twins is approximately 15 – 20%. 
 It is strongly associated with the inherited tissue type major 
histocompatibility complex (MHC) antigen HLA – DRA (Most 
specifically DR0401 and 0104) – hence family history is an important 
risk factor.  
Aetiology 
 Rheumatoid arthritis has a complex multifactorial aetiology. There 
is considerable evidence for an important genetic component. Twin 
studies indicate a concordance rate of around 20 per cent in 
monozygotic twins, although this figure is probably influenced by the 
severity of the disease in the proband. 
 Rheumatoid arthritis has many similarities to reactive arthritis, in 
which a wide range of different Gram-negative organisms are known to 
trigger the disease, infection at sites distant from the joints has not been 
identified, inspite of claims that infections of urinary tract (Proteus sp) 
may be more common in patients with rheumatoid arthritis than in 
healthy controls. Likewise, no particular organism has ever been found 
reproducibly in the joints of patients with rheumatoid arthritis, although 
there have been sporadic reports of the isolation of viruses (rubella, 
parvovirus), atypical mycobacteria, and mycoplasma. 
 Some populations appear to be at unusually high or low risk of 
developing rheumatoid arthritis, and the study of these has yielded some 
clues to its aetiology. Certain genetic markers are associated with 
 
 
 
 
rheumatoid arthritis. The risk to the first-degree relatives of probands 
with mild, non-erosive, seronegative disease (2-3 per cent) is little 
greater than in the risk in the general population. 
 The possible aetiological factors. 
  Genetic predisposition - Rheumatoid arthritis runs in families. 
It is associated with class II major histocompatability complex 
allele HLA - DR4 and HLA - DRB1. Genetic factors alone do 
not account for the disease. 
  Abnormal immune response :  Rheumatoid arthritis may be a 
manifestation of an immune - mediated response to infections 
are caused by Mycoplasma, Epstein - Barr virus, 
Cytomegalovirus, parvovirus in a genetically predisposed 
individual. 
Immune Over Activity 
 1. Presence of Serum of abnormal immunoglobulin Rheumatoid 
factor IgG and IgM. 
 2. Infiltration of synovial tissue by immunologically component 
cells, Lymphocytes, Plasma cells which are responsible for local 
production of Ig including Rheumatoid factor. 
 3. Presence of immune antigen - antibody complexes within 
leucocytes in synovial fluid and peripheral blood. 
 4. The finding of lower complement levels in synovial fluid. 
 
Signs of Symptoms of Articular Disease: 
  Pain, Swelling and tenderness may initially be poorly 
localised to the joints. Pain is aggravated by movements. 
  Generalized Morning Stiffness of > 1 hr duration is a variable 
feature and is frequent and usually greatest after periods of 
inactivity. 
  Weakness, easy fatigability, Anorexia and weight loss are 
present. 
 
 
 
 
  40oC fever on occasion may be present sometimes and 
temperature elevation of >38oC suggest the presence of 
intercurrent problem such as infection. 
  Clinically synovial inflammation causes swelling, tenderness 
and limitation of movement. Pain Originates from joint 
capsule which is abundantly supplied with pain fibres and is 
markedly sensitive to stretching or distention. Joint swelling 
results from accumulation of synovial fluid, hypertrophy of 
synovium and thickening of joint capsule. 
  RA most often causes symmetric arthritis with characteristic  
involvement of certain specific joints such as proximal 
interphalangeal joints and Metacarpophalangeal joints. 
 Synovitis of the wrist joints is a nearly uniform feature of RA 
with limitation of movements, deformity and median nerve entrapment 
(Carpel tunnel syndrome). 
 Synovitis of elbow joint often leads to flexion contracture. 
 The knee joint is commonly involved with synovial hypertrophy, 
chronic effusion and frequently ligamentous laxity. Bakers cyst is the 
extension of inflammed synovium into the popliteal fossa. 
 Arthritis in the forefoot, ankles of subtalar joints can produce 
severe pain and deformities. 
 Axial involvement is usually limited to the upper cervical spine 
with inflammation from synovial joints and bursae of the upper cevical 
spine leads to atlantoaxialsubluxation. Accompanied by pain in occiput. 
On rare occasions it  may lead to compression of spinal cord. 
A varitey of Characteristic joint changes occur 
  Laxity of supporting soft tissue structures. 
  Damage or weakness of ligaments, tendons and joint capsule. 
  Cartilage damage, muscle imbalance. 
 
 
 
 
 
 
Characteristic changes in Hand 
 1. Radial deviation at wrist with ulnar deviation of digits often with 
palmar subluxation of the proximal phalanges ‘z’ deformity. 
 2. Swan neck deformity 
   Hyperextension of the Proximal interphalangeal joint with 
compensatory flexion of distal interphalangeal joints. 
 3. Boutonniere deformity 
   Flexion contracture of the proximal interphalangeal joints of 
extension of distal interphalangeal joints. 
 4. Hyperextension of the first interphalangeal joint and and flexion 
of the 1st metacarpophalangeal joint with a consequent loss of 
thumb mobility of pinch. 
Foot  Changes in feet with eversion at the hind foot (subtalar 
joint) plantar, 
  Subluxation of metatarsal heads, widening of fore foot, 
Hallux valgus, 
  Lateral deviation and dorsal subluxation of  toes. 
Pathology 
 Rheumatoid disease is considered to be an autoimmune response 
to an unknown antigen and the antibody formed is the rheumatoid factor 
which is identified as immunoglobulin M (Mostly IgM) or IgG (Less 
commonly). The Rheumatoid factor is an IgM antibody directed against 
the FC portion of IgG antibodies. 
 Rheumatoid arthritis is an inflammation of the synovial membrane 
which becomes Oedematous and thickened with inflammatory exudates. 
Chronic persistant synovitis is the characteristic feature of rheumatoid 
arthritis. 
 The disease follows three stages. 
 i) Synovitis ii) Destruction iii) Deformity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Lymphoid follicles forms nodules with scattered cells. 
  In later stages synovium is more vascular and throws a fibrous 
exudate which gets organised into a granulation tissue and 
spreads over the articular cartilage as the pannus. 
  The articular cartilage gets lysed from the surface. 
  The inflammatory process spreads into the capsule and the 
periarticular tissue. 
  During the healing process the granulation tissue pannus 
destroys the articular cartilage uniting the joint surface and 
causing a Bony ankylosis. 
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Subcutaneous 
Osteoporosis thining of cortex and 
loss of trabeculae structure. Cyst 
formation - Subchondral erosions 
(adjacent to metaphysis) 
Destruction. 
 
Nodules 
 
 The key considerations in the pathogenesis of the disease are 1) 
the nature of the autoimmune reaction,   2) the mediators of tissue 
injury, 3) genetic susceptibility and   4) the arthritogenic antigen. 
 
 
 
 
 The autoimmune reaction in RA consists of activated CD4 + T 
cells, and probably B lymphocytes, and how they are initially activated 
are still unknown. The T cells apparently function mainly by stimulating 
other cells in the joint to produce cytokines that are central mediators of 
the synovial reaction. Although the contribution of autoreactive B cells 
has been an issue of controversy, there is increasing evidence that 
immune complex deposition may also play some role in the joint 
destruction. Perhaps, the major advances in our understanding of the 
disease have been a better appreciation of the actual mediators of joint 
injury. Cytokines are believed to play a pivotal role, and the most 
important of these cytokines are TNF and K-1. Both are probably 
produced by macrophages and synovial lining cells that are activated by 
the T cells in the joint TNF and IL-1 in turn, stimulate synovial cells to 
proliferate and produce various mediators of inflammation (such as 
prostaglandins), and matrix metallo proteinases that contribute to 
cartilage destruction. Activated T cells and synovial fibroblasts also 
produce RANKI, which activates osteoclasts and promotes bone 
destruction. Thus a chain of events is set up that leads to progressive 
joint damage. The hyperplastic synovium rich in inflammatory cells 
become adherent to and grow over the articular surface, forming a 
pannus, and stimulates resorption of the adjacent cartilage. In the end, 
the pannus produces sustained, irreversible cartilage destruction and 
erosion of subchondral bone. The realization of the important roles of 
TNF and IL-1 is the basis for the successful use of anticytokine therapy, 
especially against TNF. 
 Genetic susceptibility is a significant component of the 
development of RA. There is a high rate of concordance between 
monozygotic twins and a well defined familial predisposition. Multiple 
gene loci are beleived to be responsible for susceptibility to the disease, 
but most of these have not been identified yet. One susceptibility gene 
that is known is in the class II HLA locus and specifically a region of 4 
 
 
 
 
amino acids located in the antigen binding cleft that is shared in HLA 
DR BI 0401 and 0404 alleles. This HLA-DR allele may bind and display 
the arthritogenic antigen to T cells, although there is no formal evidence 
in support of this idea. 
 The antigen that trigger autoimmunity and precipitate the reaction 
are not known. There has been great interest in exploring microbial 
antigens, as the initiating triggers, but no firm evidence has definitively 
identified a microbial organism as an etiologic agent in rheumatoid 
arthritis. 
EXTRA – ARTICULAR MANIFESTATIONS 
Systemic: 
• Fever 
• Weight loss 
• Fatigue 
• Susceptibility of infection 
Vasculities: 
• Digital arteritis 
• Ulcers 
• Pyoderma gangrenosum 
• Mononeuritis multiplex 
• Visceral 
Musculoskeletel: 
• Muscle wasting 
• Tenosynovitis 
• Bursitis 
• Osteoporosis 
Cardiac: 
• Pericarditis 
• Myocarditis 
• Endocarditis 
• Conduction defects 
• Coronary vasculitis 
• Granulomatous arthritis 
Haematological: 
• Anaemia 
• Thrombocytosis 
• Eosinophilia 
Nodule: 
• Sinuses 
• Fistula 
Lymphatic: 
• Spleenomegaly 
• Felty’s syndrome 
Pulmonary: 
• Nodules 
• Pleural effusion 
 
 
 
 
• Fibrosing alveolitis 
• Bronchiolitis 
• Kaplan’s syndrome 
Occular: 
• Episcleritis 
• Scleritis 
• Scleromalacia 
• Kerato conjunctivitis sicca 
Neurological: 
• Cervical Cord compression 
• Compression neuropathies 
• Peripheral neuropathy 
• Mononeuritis multiplex 
• Amyloidosis 
Frequency Joint involvement in Rheumatoid arthritis 
1. MCP / MTP / PIP joints   - 90% 
2. Knee, ankle, wrist joints   - 80% 
3. Shoulder joint   - 60% 
4. Hip, elbow, acromion   - 50% 
5. Cervical spine   - 40% 
6.  Temperomandibular and Sternomastoidjoints  - 30% 
7. Cricoarytenoid joint   - 10% 
Diagnosis 
The revised criteria of 1987 (American college of Rheumatology) 
Criteria Comments 
1. Morning stiffness Duration > 1 hr lasting > 6 weeks 
2. Arthritis of atleast 3 areas Soft tissue swelling or exudation 
lasting > 6 weeks 
3. Arthritis of hand joints Wrists, metacarpophalangeal 
joints or proximal interphalangeal 
joints lasting > 6 weeks 
4. Systemic Arthritis At least one area, lasting > 6 
weeks 
5. Rheumatoid Nodules As observed by the physician 
6. Serum Rheumatoid factor As assessed by a method positive 
 
 
 
 
in less than 5 percent of control 
subjects. 
7. Radiographic changes As seen on anteroposterior films 
of wrists and hands 
 
Rheumatoid arthritis is diagnosed if 4 of the 7 criteria are met. 
 
DISEASE PREVALENCE AND ONSET 
 Rheumatoid arthritis may occur at any age but has a peak 
incidence in the fifth decade. The lifetime incidence of the disease in 
women (1.8 per cent) is three times more than in males (0.5 per cent) 
and the prevalence of the disease in women over 65 years old is more 
than 5 per cent. The sex difference is most pronounced (as high as 6:1) 
in those with early onset disease but is almost equal by the age of 65. 
The disease starts twice as commonly in winter. 
Explosive onset 
 In about 10 per cent of cases the onset of the disease is very rapid 
even overnight, with severe symmetrical polyarticular involvement. 
Systemic onset 
 This is particularly common in middle-aged men in whom non-
articular feature may dominate the clinical picture. Fever, myalgia, 
weight loss, anaemia, pleural effusions, and vasculitic lesions may be 
severe, sometimes in the absence of marked joint pathology.  
Insidious onset 
 The majority of cases of rheumatoid arthritis develop insidiously 
over weeks or months, with gradually increasing joint involvement seen 
in up to 70 per cent of cases. 
Polymyalgic onset 
 Limb girdle muscle symptoms may precede the onset of   
arthropathy, particularly in the elderly. 
 
 
 
 
 
Mono-and pauci-articular onset 
 In young women there may initially be very limited joint 
involvement, particularly involving the knees. 
Joint features 
 Rheumatoid arthritis is typically a distal, symmetrical, small-joint 
polyarthritis involving the proximal interphalangeal and 
metacarpophalangeal joints of the hands, the wrists, 
metatarsophalangeal joints, ankles, knees, and cervical spine. The 
shoulders, elbows, and hips are less frequently involved, but can be a 
major source of morbidity. Any synovial joint in the body may be 
affected, including the cricoarytenoid and the temperomandibular joints. 
In addition, periarticular synovial structures, such as bursae and tendon 
sheaths, are commonly inflammed. 
 The most common symptoms are pain and pronounced stiffness. 
The latter frequently exhibits a diurnal rhythm, worse on rising in the 
morning and then recurring towards the evening, perhaps reflecting the 
diurnal variation in plasma cortisol levels. 
  Gentle activity may alleviate the symptoms but is followed by 
stiffening or ‘gelling’ with subsequent inactivity. The affected joints are 
frequently tender, swollen and warm and there may be limitation of both 
active and passive movement. Muscle wasting serves to accentuage the 
local swelling of the joint, which is in part due to proliferation of the 
synovial tissue and in part to synovial effusion within the joint. 
Progressive destruction of the articular cartilage, subchondral bone, and 
periarticular soft tissues eventually combine to produce the 
characteristic deformities seen in long-standing rheumatoid arthritis.    
 In parallel with these clinical changes there are characteistic 
radiological appearance which may be helpful in the diagnosis of early 
rheumatoid arthritis and in monitoring its progress. In the early stages of 
the disease it is common for the first evidence of erosions to be in the 
feet. Diagnostic views in Radiological changes include: 
 
 
 
 
1. soft-tissue swelling 
2. juxta-articular osteoporosis 
3. loss of joint space due to erosion of the articular cartilage 
4. bone erosions at the point of attachment of the synovium and 
5. joint deformities. 
 
Hands and wrists 
 The appearance of the hands in rheumatoid arthritis is highly 
characteristic. Early in the disease there may be soft-tissue swelling 
around the affected joints. Involvement of the proximal interphalangeal 
joints give a spindle-shaped appearance to the fingers, and soft-tissue 
swelling can be observed over the ulnar styloid, and in the second and 
third metacarpophalangeal joints. Distal interphalangeal joint 
involvement is less common (about 15 per cent of cases) but rheumatoid 
arthritis may sometimes be superimposed on pre-existing osteoarthritis 
of these joints. 
 Tenosynovitis of the long flexor tendons in the palm of the hand 
may exacerbate stiffness of the finger and cause ‘trigger finger’. This 
may be associated with palpable crepitus over the tendon on active or 
passive movement of the corresponding finger. Similar synovitis at the 
wrist within the flexor retinaculum may cause compression of the 
median nerve with the typical features of carpal tunnel syndrome - 
paresthesiae of the first three digits and the radial side of the ring 
finger, wasting and weakness of the thenar mucles, with night pain 
frequently extending proximally as far as the elbow: typically these 
symtoms can be relieved by shaking the hand or movement of the 
fingers. Tinel’s sign is sometimes positive but relatively insensitive. 
Phalen’s sign (pressure over the carpal tunnel with the wrist in flexion) 
may be more useful, not only because it is more frequently positive but 
also because it reproduces the symptoms accurately. The diagnosis can 
be confirmed if necessary by nerve conduction studies. 
 
 
 
 
 On the dorsal surface of the wrist, synovitis of the extensor 
tendons is common and may lead to rupture. A ‘dropped finger’ 
affecting the little finger is an important indication for surgical 
exploration and synovectomy. 
 Bull’s horn deformity due to rupture of the extensor communis 
tendon from synovitis near the ulnar styloid. Selective sparing of the 
extensor indicis proprius and extensor digiti minimi tendons has in this 
instance preserved the ability to point the index and little finger 
independently 
 Volar subluxation of the fingers at the metacarpophalangeal 
joints occurs as a result of destruction of the articular cartilage, and 
subsequent instability of these joints. Since the flexor tendons provide 
the strongest force acting across these joints progressive subluxation 
towards the palm may develop, leaving the metacarpal heads relatively 
prominent. 
 Ulnar deviation and subluxation of the fingers as a result of 
instability of the metacarpophalangeal joints. The fingers may tend to 
drift in an ulnar direction because of the ulnar vector of the action of 
both the flexor and extensor finger tendons. The process may be 
exacerbated by radial deviation of the carpus and also by ulnar 
subluxation of the extensor tendons if the support which usually hold 
them in place over the centre of the metacarpophalangeal joints are 
weakened by synovitis. 
 Swan neck deformities occur following volar subluxation of the 
proximal phalanges at the metacarpophalangeal joints, with subsequent 
contracture of the intrinsic muscles which become extensors rather than 
flexors of the proximal interphalangeal joints. Compensatory flexion of 
the distal interphalangeal joints occurs as a result of a tenodesis effect 
as the flexor digitorum profundus tendon is stretched over the 
hyperextended proximal interphalangeal joint. 
 
 
 
 
 Boutonniere (button-hole) deformity occurs when a chronic 
effusion within the proximal interphalangeal joint stretches or even 
ruptures the dorsal slip of the extensor hood, allowing dorsal migration 
of the joint through the discontinuity. A similar process at the 
carpometacarpal joint of the thumb may give rise to the Z-thumb 
deformity. 
 Piano-key sign can be detected when weakening of the distal 
radio-ulnar ligament by synovitis allows the distal ulna to migrate 
dorsally so that it overrides the radius (caput ulnae syndrome). The ulna 
can be depressed by pressure like a piano key (while the patient emits a 
note!). Progressive distruction of the carpal joints may be followed by 
volar subluxation and ultimately ankylosis. 
 Carpal collapse and fusion may accumulate in the disease, 
particularly in those with an early onset rheumatoid arthritis, when 
instability of the wrist may lead to collapse of the carpal bones, causing 
foreshortening of the carpus and, ultimately, spontaneous fusion of the 
wrist. 
Elbows and shoulders 
 Involvement of the elbows is less common than of the wrist but 
severe destruction may occur, leading to pronounced deformity and 
disability. 
 The radiohumeral joint is more commonly symptomatic than the 
humero-ulnar joint and presents problems particularly with pronation / 
supination. Periarticular structures (olecranon bursa, ulnar nerve) may 
also affected by synovitis and subcutaneous nodules are commonly 
found on the extensor surface of the forearm close to the elbow. 
 There may be inflammation of the subacromial bursa or 
supraspinatus tendon in addition to glenohumeral joint synovitis, 
producing a typical painful syndrome. Involvement of the 
acromioclavicular joint can give rise to pain particularly with overhead 
activities. 
 
 
 
 
 
Knees 
 Synovial proliferation is usually most obvious in the suprapatellar 
pouch and there may be pronounced wasting of the quadriceps as a 
result of reflex muscle inhibition. Synovial effusion typically produces 
posterior knee pain in the early stages by stretching the posterior 
capsule of the joint. This may lead to the development of a popliteal 
cyst communicating with the joint via a valve-like opening which does 
not easily allow fluid back into the joint. Rupture of the joint or a 
popliteal cyst may cause extravasation of highly irritant synovial fluid 
into the calf where the inflammation and swelling may mimic a deep 
vein thrombosis. These two pathologies can sometimes coexist because 
there may be partial obstruction to the venous return by the presence of 
an extensive popliteal cyst. 
 Tricompartmental damage to the articular surfaces of the knees is 
the usual outcome of late disease and may cause severe instability of the 
joint as the collateral and cruciate ligaments become lax. Valgus 
deformities of the knees are the usual consequence of loading such 
unstable joints, and are often combined with a degree of fixed flexion 
deformity. Pain may also arise from periarticular structures, such as the 
insertion of the collateral ligaments which are chronically under strain 
in the unstable knee joint. Even in the end stages of destruction of the 
knee joint. 
Hips 
 Involvement of the hips in rheumatoid arthritis is relatively 
uncommon overall. Pain is usually experienced in the groin and the 
buttock but may radiate to the knee, sometimes mimicking knee 
arthritis. Rotation and abduction of the hip are reduced before flexion, 
but ultimately fixed flexion deformity of the joint may occur.   
 
 
 
 
 
 
AXIAL SKELETON 
 Involvement of the sacroiliac joints is rare in rheumatoid arthritis. 
Spinal arthritis is common, up to 80 per cent of patients demonstrating 
radiological evidence of the disease in the cervical spine. This may be 
asymptomatic but the most frequent result is painful limitation of 
movement, often in several planes. The most common radiological 
abnormalities consist of osteoporosis, erosion of the zygopophyseal 
joints, erosions of the vertebral end plates, and loss of disc space in the 
absence of florid osteophytosis.  
 There may be evidence of atlantoaxial subluxation in up to 25 per 
cent of patients. Serious erosive change in the cervical spine is more 
likely in patients who have pronounced peripheral joint disease. 
Other joints 
 Hoarseness of the voice may occasionally be caused by effusion 
within the cricoarytenoid joints. Temporomandibular joint disease 
causes pain on chewing and may particularly restrict opening of the 
mouth. 
Rheumatoid nodules 
 Subcutaneous and intracutaneous nodules are a hallmark of the 
disease, occuring in about one-quarter of patients. They are discrete, 
firm, non-tender swellings varying from a new millimetres to several 
centimetres in size, and in rare instances, usually seropositive males, 
they may occur in the absence of typical articular disease (rheumatoid 
nodulosis). They occur most frequently on the extensor surface of the 
forearm and olecranon, sites where repeated minor trauma from leaning 
could initiate their formation. They also commonly occur around 
tendons, including the Achilles, the flexor and extensor tendons of the 
fingers, and over the sacrum. Sometimes superficial nodules may break 
down with ulceration of the surrounding skin. 
 Histological examination of these nodules reveals central fibrinoid 
necrosis surrounded by palisades of fibroblasts and chronic 
 
 
 
 
inflammatory cells, suggesting a combination of proliferative and 
destructive tissue responses. Rheumatoid nodules may also develop in 
many other tissues including the eye (scleromalacia), pleura, 
pericardium, and parenchyma of the lungs and heart (where they may be 
found at autopsy in as many as 10 per cent of patients). They sometimes 
occur on the vocal cords and very occasionally they may cause 
dysfunction of the heart valves or conducting tissue. 
Anaemia 
 A moderate normochromic normocytic anaemia is an almost 
invariable finding in active rheumatoid arthritis. In the chronic anaemia 
of rheumatoid disease the blood picture is usually normocytic and 
normochromic or hypochromic (but rarely microcytic). Iron-binding 
capacity is typically reduced in active rheumatoid arthritis; normal or 
slightly raised levels in the presence of a low serum iron are therefore 
highly indicative of iron deficiency. In contrast, as part of the acute 
phase response, ferritin levels are typically elevated in active 
rheumatoid arthritis unless there is iron deficiency. The typical anaemia 
of chronic disease seen in rheumatoid arthritis correlates closely with 
the sedimentation rate as a marker of disease activity and does not 
respond to iron, folic acid or Vitamin B12.                                                                                     
Platelets:The platelet count is commonly increased increased to a level 
greater than 5 x 104 in active disease and this may also occur when 
there is active bleeding from the intestine. 
Vasculitis 
 Vasculitis is more common in patients with high levels of IgM 
rheumatoid factor and severe joint disease, although the activity of the 
synovitis and extra-articular disease is often temporally dissociated. Its 
incidence increase with the duration of the disease, but occasionally it 
may be present from the outset, even rarely, in the absence of joint 
disease. 
 
 
 
 
 Rheumatoid vasculitis is associated with significant mortality but 
this can be significantly reduced with appropriate therapy. 
Lung involvement 
 Pleurisy has an incidence of about 1 per cent overall but pleural 
effusions due to rheumatoid arthritis may go undetected. Pleural 
involvement is five times more common in men than in women and often 
needs differentiation from other causes, particularly when other 
systemic features, such as weight loss and fever, are present. The fluid 
has raised protein, low glucose, and low complement levels and is 
typically positive for rheumatoid factor. Pleural biopsy may reveal 
rheumatoid granulomata, like an ‘opened-out rheumatoid nodule’, but 
typically there is the appearance of non-specific inflammation which 
does not allow differentiation from other causes of pleurisy. 
 Nodules are more common in the upper than the lower zones and 
may be single or multiple. Cavitation may occasionaly lead to 
haemoptysis. Pulmonary fibrosis is common in rheumatoid arthritis but 
is often subclinical. Ten per cent of patients have radiological evidence 
of fibrosis and many more have evidence of impaired vital capacity and 
gas transfer Classical fibrosing alveolitis occurs in     2 % of patients 
with rheumatoid arthritis and causes progressive, clubbing of the 
fingers, fine late-inspiratory crepitations, and lower-zone 
reticulonodular shadowing on the chest radiograph. 
 Obliterative bronchiolitis is a rare but rapidly progessive and fatal 
process manifesting with an acute onset of breathlessness. Widespread 
small airways obstruction is present in the absence of alveolar fibrosis 
and there is little evidence of inflammation. 
 Many patients with rheumatoid arthritis have evidence of airways 
obstruction irrespective of their smoking habits. Bronchiectasis also 
appears to be more common in those with the disease and to predate its 
onset.  
 
 
 
 
 Valvulitis may be apparent in 20 per cent of cases but is rarely 
symptomatic during life. Granulomatous thickening of the cusps of the 
aortic valve occurs more frequently than in the mitral valve but only 
produces incompetence of the valve. Acute aortic regurgitation 
following perforation of one of the cusps is described. Autopsy studies 
reveal a patchy myocardial fibrosis in about one-sixth of patients and 
myocardial nodules can be found in some patients with small-vessel 
vasculitis. Myocardial infarction resulting from necrotizing vasculitis 
during life seems to be very low. 
Eyeinvolvement                                                                     
 This is common rheumatoid arthritis and may be due to localized 
tissue involvement or as part of a more generalized disorder involving 
the exocrine glands - Sjogren’s syndrome. Exceptionally there may be 
diplopia resulting from stenosing tenosynovitis of the superior oblique 
tendon (Brown syndrome). 
 Sjogren’s syndrome is characterized by diffuse infiltration of the 
exocrine glands and other tissues by lymphocytes, resulting in 
destruction and glandular insufficiency. The syndrome occurs in one-
fifth of patients with rheumatoid arthritis (secondary Sjogren’s 
syndrome) 
 Typical symptoms consist of pain, erythema and grittiness in the 
eyes, photosensitivity, and stickness associated with adherent strands of 
mucus. Secondary bacterial infection is relatively common due to the 
loss of lysozymes, bacteriostatic agents normally present in tears. 
Corneal damage may occur. 
 Extraglandular involvement is less common in secondary 
Sjogren’s syndrome than in the primary disease, but half of those with 
rheumatoid arthritis exhibit at least some degree of parotid gland 
enlargement. General malaise is common and cutaneous vasculitis, 
peripheral neuropathy, renal tubular acidosis, interstitial pulmonary 
fibrosis, and myositis may all coincide. 
 
 
 
 
 Episcleritis usually appears as a raised lesion in the anterior sclera 
with hyperaemia of the deeper layers. The lesions are often transient but 
may be associated with vasculitis. 
 Scleritis is less common but potentially more serious since it may 
lead to progressive  thinning of the sclera (scleromalacia) and even 
perforation. Keratolysis (corneal melting) and limbal guttering are rare 
complications of vasculitis of the circumcorneal vessels which can also 
cause perforation. 
Peripheral nerve involvement 
 A mild glove and stocking sensory neuropathy is relatively 
common in rheumatoid arthritis but is usually benign and does not imply 
inflammation of nervous tissue. However, there may be lymphocytic 
infiltrates of the dorsal root ganglia in Sjogren’s syndrome. In contrast, 
the presence of a mixed sensorymotor neuropathy or mononeuritis 
multiples is indicative of underlying vasculitis of the vasa nervorum.                                              
Muscle involvement 
 In rheumatoid arthritis muscle involvement is usually attributed to 
the reflex inhibition and wasting resulting from severe joint pain. Focal 
lymphocytic infiltration may be present on muscle biopsy, but its 
relevance to symptoms is in doubt and there is no increase in muscle 
enzyme concentrations in the serum to suggest active myositis. 
Liver involvement 
 This is evident in about 10 percent of patients with active disease. 
There may be mild hepatosplenomegaly and asymptomatic elevation of 
the serum alkaline phosphatase. Minor degrees of fatty change, Kupffer 
cell hyperplasia, and lymphocytic infiltration of the poral tracts may be 
seen. 
The Felty syndrome 
 Lymphadenopathy is common in patients with rheumatoid 
arthritis, biopsies showing nodular hyperplasia. It is most obvious in 
patients with the Felty syndrome (rheumatoid arthritis, splenomegaly, 
 
 
 
 
and leucopenia). Other extra-articular features are frequently present 
and include anaemia, thrombocytopenia, persistent vasculitic leg 
ulceration, cutaneous pigmentation, weight loss, and recurrent infection. 
It is uncommon (less than 1 per cent of all cases) and rarely develops in 
patients who have had the disease for less than 10 years. 
Investigation 
No test is specific for diagnosiing Rheumatoid arthritis, 
A. Haematological: 
 1.  ESR - Increased in active stage. 
 2.  Serum proteins - Hyperglobulinaemia with elevation of Gamma 
and Alpha 2 globulins hypoalbuminaemia during acute phase and 
C-reactive protien (CRP) 
 WBC count is usually normal, but a mild leucocytosis may be 
present. Eosinophilia when present usually reflects severe systemic 
disease. 
B. Immunological: 
I. Rheumatoid Factor (RF): 
  Latex screening positive 
  Latex test positive 
  Sheep Caps Agglutination Test (Roose Waaler) (SCAT) 
  Differential Agglunination Test (DAT) 
  Human Erythrocyte Agglutination Test (HEAT) 
 
 Rheumatoid Factor (RF) is an auto antibody (Antibody directed 
against an organism’s own tissues). It is an antibody against the Fc 
portion of IgG, which is itself an antibody. 
 Rheumatoid Factor (RF) is evaluated in patients suspected of 
having any form of arthritis even though positive results can be due to 
other causes, and negative results do not rule out the disease, but in 
combination with signs and symptoms. 
 
 
 
 
 
Immunological 
The amount of Rheumatoid factor in blood can be measured by, 
  Agglutination Test: Blood is mixed with tiny rubber (latex) 
beads that are covered with human antibodies. If rheumatoid 
factor is present, the latex beads clump together (agglutinate). 
Normal Titre is 1:20 - 1:40 or less Rheumatoid arthritis, titre 
is greater than 1:20 - 1:40. 
Auto antibodies other than Rheumatoid Factor in Rheumatoid Arthritis. 
  Antiperinuclear factor 
  Antikeratin antibodies 
  Antibodies to cyclic citrullinated peptide (CCP) 
  Antibodies to SA, p6 and calpastatin. 
Of this Anti-CCP Antibodies stand out as the most useful clinically, 
especially in defining Rheumatoid arthritis in early stages. 
 
Rheumatoid Factor (RF) may also be elevated in 
 Chronic hepatitis, Any chronic viral infection, Leukemia, 
Dermatomyositis, Systemic lupous erythematosus (SLE), Infectious 
mononucleosis and Systemic sclerosis. 
II. Anti Nuclear Antibodies: 
  Synovial fluid analysis confirms the presence of 
inflammatory arthritis. Fluid may show positive Roose - 
Waaler test in joint fluid, before it can be detected in blood. 
Also it may show neutrophils or monocytes inclusion bodies. 
III. Synovial biopsy: 
 Villus formation with thickening of synovial layer and infiltration 
with abnormal cells. 
IV. Radiographic Evaluation: 
  Soft tissue swelling 
  Juxta articular osteoporosis 
  Erosion of joints margins 
 
 
 
 
  Joint spaces are decreased 
  Deformities 
  Atlanto-axial subluxation 
  Subchondral erosions and cyst formation 
  Fibrous and bony ankylosis develops in the late stages. 
V. Arthroscopy: 
 In acute Rheumatoid Arthritis synovium is oedematous, diffusely 
erythematous and friable. In more chronic conditions it becomes 
thickened. 
VI. Renal Biopsy: 
 Indicated in cases of reduced tubular or glomerular function. 
VII. Pulmonary Biopsy: 
 Used to distinguish Rheumatoid nodules from carcinoma or to 
establish diagnosis of fibrosing alveolitis. 
VIII. Ultra Sound 
IX. Scintigraphy 
X. CT Scanning 
 Shows cartilage and sub-chondral bone damage long before 
conventional x rays. 
XI. MRI 
XII. Urine analysis 
XIII. Biochemical analysis 
XIV. Anti CCP antibodies 
 (Cyclic citrullinated peptide antibodies) 
XV. Genetic tests 
 HLADRB1 Typing to detect the presence of ‘Shared epitope’. 
XVI. Antinuclear antibody assay (ANA) 
XVII. Bone density test to check for bone loss 
 Patients treated by simple methods show that after 10 years 50% 
will have improved and 50% deteriorated. 
 
 
 
 
 Remissions of disease activity are most likely to occur during the 
first year. The median life expectancyof persons with Rheumatoid 
arthritis is shortened by 3 to 7 years. 
 
DIFFERENTIAL DIAGNOSIS OF RHEUMATOID ARTHRITIS 
 Sero negative spondyloarthropathy included following 
Rheumatoid like conditions were the serum is negative for Rheumatoid 
factor. They are, 
1. Ankylosing spondylitis: 
 Ankylosing spondylitis is a chronic, progressive and crippling 
disease affecting the spine. The exact etiology is unclear. Ankylosing 
spondylitis has been found to be more prevalent in certain races and 
hence shows a genetic predisposition. It is related to certain tissue types 
of the human leukocytic antigen (HLA) system. The majority of 
ankylosing spondylitis patient is to belong to HLA-B27 groups. 
 The disease occurs in the 3rd and 4th decades of life and is more 
common in males. The patients present with complaints of diffuse pain 
in the back and vague pain in other joints. 
2. Reiter’s disease: 
 Reiter’s disease characterised by triad of polyarthritis, urethritis, 
conjunctivitis. The joint condition is an acute polyarthritis resembling 
Rheumatoid arthritis. It does not cause destructive changes in the joint 
structures. The urethritis is non-gonococcal but the exact organism is 
not known. 
3. Psoriatic arthritis: 
 Psoriatic arthritis is a polyarthritis seen in about 10% of patients 
with psoriasis. 
  The most common type is the one involving the distal 
interphalangeal joints of the hands and feet with psoriatic 
nail joints. Metacarpophalangeal joints are never involved in 
psoriatic arthritis. 
 
 
 
 
  Arthritis multilens is a severe form where there is marked 
destruction of joints. 
  Symmetrical polyarthritic type 
  Oligo arthritic type 
  Spondyloarthritic type. 
4. Enteropathic arthritis: 
 Chronic inflammatory bowel disease like regional enteritis 
(Crohn’s disease) and ulcerative colitis are associated with arthritic 
lesion in about 10% of the cases. There is peripheral  involvement of the 
spine. The joint condition shows remissions and exacerbations along 
with activity of the underlying bowel disease. 
5. Sjogren’s Syndrome: 
 Approximately 10 to 15% of patients with Rheumatoid arthritis, 
mostly women develop Sjogren’s syndrome, a chronic inflammatory 
disorder characterised by lymphocytic infiltration of lacrimal and 
salivary glands. This leads to impaired secretion of saliva and tears and 
results in the sicca complex: dry mouth (xerostomia) and dry eyes 
(keratoconjunctivitis sicca). 
 Patients with Sjogren’s syndrome have a variable expression of 
disease in other exocrine glands. This is manifested clinically as dry 
skin, decreased perspiration, dry vaginal membranes, or a nonproductive 
cough. 
 Commonly, there is also a polyclonal lymph proliferative reaction 
characterised by lymphadenopathy and spleenomegaly. This can mimic 
and rarely transform into a malignant lymphoma. 
Clinical manifestations: 
  Keratoconjuctivitis and Xerostomia 
  Renal involvement produces mild interstitial nephritis that 
may result in renal tubular acidosis. 
  Sensory polyneuropathy and mononeuritis multiplex. 
 
 
 
 
  Pulmonary involvement generally takes the form of an 
interstitial pneumonitis which is usually a little clinical 
significance. 
Complications 
1. Amyloidosis: 
 It is a complication of prolonged active disease and is formed in 
25% to 35% of patients at autopsy, making Rheumatoid Arthritis a 
leading cause of secondary amyloidosis. 
2. Fixed deformities: 
 The perils often the common place ones resulting from ignorance 
and neglects. Early assessment and planning should prevent postural 
deformities that will result in joint contractures. 
3. Muscle weakness: 
 Even mild degree of myopathy or neuropathy when combined with 
prolonged inactivity may lead to profound muscle wasting and 
weakness. This should be prevented by physiotherapy and pain control if 
possible.   
4. Joint rupture: 
 Occasionally the joint lining ruptures and synovial contents spill 
into the soft tissue.  
5. Systemic vasculitis: 
 This is a rare but potentially serious complication. 
MANAGEMENT 
Treatment 
 Treatment has five main aims. 
  Relief of pain 
  Reduction of inflammation 
  Minimizing undesirable side effects 
  Preservation of muscle strength and joint function 
  Return as rapidly as possible to a normal life style. 
 
 
 
 
 A variety of physical therapy modalities may be useful in 
decreasing the symptoms of Rheumatoid Arthritis. Exercise is directed 
at maintaining muscle strength and joint mobility. 
Drug Therapy: 
 The drugs used are as follows: 
1. Non-steroidal anti-imflammatory drugs (NSAIDs) 
2. Disease modifying antirheumatoid drugs (DMARDs) 
• Methotrexate 
• Gold 
• Penicillamine Antimalarials 
• Sulphasalazine 
3. Steriods 
4. Cytotoxic drugs 
• Azathioprine 
• Leflunomide 
• Cyclosporine 
• Cyclophosphamide 
5. Newer drugs 
• TNF receptor antogonist – etanarcept 
• TNF receptor antibody – infliximab 
• IL-1 receptor antagonist - anakinra 
Surgical Treatment 
• Synovectomy 
• Osteotomy 
• Arthroplasty 
• Excision arthroplasty 
• Replacement arthroplasty 
• Arthrodesis 
• Tendon transfer operation for correcting deformities 
• Excision of the metacarpophalangeal joints in case of gross 
deformities 
 
  
  
 
 
 
 
 MATERIALS AND METHODS 
In this study 12 cases were admitted in in-patient ward and the other 28 
cases were seen in Out-patient ward. 
Selection of cases: 
Certain inclusive Criteria were followed for the selection of cases as 
follows. 
 Sex- both male and female. 
 Patients having symptoms of arthritis of more than three 
joint,involvement of the smaller joints pain, swelling, morning stiffness, 
crepitations, restricted movements of the affected joints. 
 Patients who are willing to undergo radiological investigation and give 
blood for laboratory investigations. 
 Patients willing to sign the informed consent stating that he/she will 
consciously stick to the treatment for 40 days. 
Diagnosis of the cases: 
         Diagnosis was made by conducting all the necessary investigations in siddha 
and by thorough clinical examination and laboratory findings as per modern 
medicine methodology. 
 
In siddha system the following aspect were taken into consideration: 
1. Examination of uyir thathukkal 
2. Ennvagai thervugal 
3. Udal thathukalin Nilaigal 
 
 
 
 
4. Neerkuri, Neikuri. 
In modern, the following diagnosis were made. 
Hematological investigations: 
 1. Total W.B.C. count 
 2. Differential W.B.C count 
 3. Erythrocyte sedimentation rate 
 4. Haemoglobin percentage 
 5. Blood Sugar 
 6. Blood Urea 
 7. Serum Cholesterol 
Urine Analysis: 
 Albumin,Sugar,Deposits                                                      
Motion Analysis: 
 Ova,Cyst                                                                               
Specific investigations: 
1. Rheumatoid factor 
2. Radiographic evaluation 
3C-reactiveprotein                                                                          
Evaluation of clinical parameters 
 In this study the detailed clinical history was taken from the 
patient. 
 Special attention was laid on the pain, swelling and stiffness, 
regarding the nature of pain, site of occurence, mode of onset and 
severity. 
 The seasonal variation and precipitating factors like emotional 
stress, trauma and change of climate were enquired. 
 Constitutional symptoms like easy fatigability, anorexia, loss of 
weight, pyrexia were noted. 
 
 
 
 
 Extra-articular features like conjunctivitis, Iritis, Episcleritis 
Vasculitis etc were noted. Socio-Economic status, family History and 
other significant disease already treated were noted. 
Selection of drugs 
 Selection of drugs was made from the elaborate study of various siddha 
literatures and finally the drugs were selected from Siddha research pharmacopia 
and Athmaratchamirtham ennum vaidya sara sangragagam. 
The trial drugs selected are 
I. Myeliragathi ennai as internal medicine and  
II. Vaengaipattai Thyllam as external medicine. 
LINE OF TREATMENT: 
 The day before the internal medicine started Sitthathi ennai was given at 
early morning for purgation to correct the deranged humors (Vali,Azal,Iyam)to all 
the patients.In case of severe conditions the Sitthathi ennai was given for 3 days 
continuously,and in some patients it was given once in 15 days 2 or 3 times.  
 After the administration of Sitthathi ennai is completed the trial drugs are 
administrated. 
1. MYELIRAGATHI ENNAI  as Internal medicine 
4ml in ginger juice for 2 times a day 
2. VAENGAIPATTAI THYLAM  as external medicine 
    This oil was given only for external use to take bath weekly once. 
           All the patients were advised to maintain dietary regimen (or) pathiyam to 
avoid interaction with drug. 
       Some complementary therapies like ottradam, kattu, Varmam based massage 
and asanas (simple exercises), mutthirai were manipulated. 
 
 
 
 
CLINICAL ASSESSMENTS: 
 The drugs were subjected to phytochemical and Pharmacological analysis. 
 Required information was collected from each patient by using the  forms 
mentioned in protocol. 
 The clinical assessments for In- patients was made daily and recorded. 
  The clinical assessments for out- patients were recorded regularly in each 
visit. 
  A separate case sheet was maintained for each and every patient 
 The laboratory investigation was done before and after treatment and 
recorded in the appropriate form. 
  All the patients were screened for side effects and adverse effects. 
  The outcome is assessed by the reduction of symptoms with the help of 
pain assessment scale. 
 All the patients were advised for the further follow up. 
 The drugs were selected after a detailed study of various Siddha 
literatures. 
 The pharmacological study and the Bio-chemical study of both 
the drugs were conducted at the Department of Pharmacology and 
Department of Biochemistry, Govt. Siddha Medical College, 
Palayamkottai respectively. 
  
 
 
 
 
OBSERVATION AND RESULTS 
 
Result were observed with respect to following criteria. 
1. Sex 
2. Age 
3. Food 
4. Economic Status 
5. Mukutrakalam 
6. Paruva Kalam 
7. Thinai 
8. Mukkutra Theory 
9. Ual Kattugal 
10. Enn Vagai Thervugal 
11. Naadi 
12. Neikuri 
13. Duration of illness 
14. Onset of disease 
15. Clinical features 
16. Involvement of Locomotor System 
17. Associated disease 
18. Grade 
19. Results 
a. Effect of the Trial drug alone 
b. Effect of the Trial drug alone with Complementar Medicine. 
20. Effect of Drug Theraphy 
 
 
 
 
 
1. Sex distribution 
S.No Sex No. of cases (out of 40) % 
1. Male 4 10 
2. Female 36 90 
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2. Age of distribution 
S.No Age ( in years) No. of cases % 
1. 10 – 30 7 17.5 
2. 31 – 40 12 30 
3. 41 – 50 7 17.5 
4. 51 – 60 12 30 
5. 61 & above 2 5 
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3. Food habits 
S.No. Food habits No. of cases % 
1. Vegetarian 2 5 
2. Non-Vegetarian 38 95 
 
4. Socio Economic Status 
S.No Socio Economic Status No. of cases % 
1. Poor 10 25 
2. Middle class 26 65 
3. Rich 4 10 
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5. Mukkutra Kalam 
S.No Kalam No. of cases % 
1. Vatham (- 33 years) 10 25 
2. Pitham (33 – 66 years) 30 75 
3. Kabam (66 & above) - - 
 
6. Paruva Kalam 
P.K. No. of cases % 
1. Elavenil  
(Chithirai – Vaikasi) 
(April 15 – June 15) 
-  
2. Muthuvenil  
(Aani – Aadi) 
(June 15 – August 15) 
8 20 
3. Kaar 
(Aavani – Purattasi) 
(August 15 – October 15) 
10 25 
4. Koothir 
(Ippasi – Kaarthikai) 
(Oct. 15 – Dec. 15) 
20 50 
5. Munpani 
(Markazhi – Thai) 
(Dec. 15 – Feb. 15) 
2 5 
6. Pinpani 
(Maasi – Panguni) 
(Feb. 15 – April 15) 
- - 
 
 
 
 
 
 
 
 
7. Thinai 
S.No. Thinai No. of cases % 
1. Kurinji - - 
2. Mullai - - 
3. Marutham 40 100 
4. Neithal - - 
5. Paalai - - 
 
8. Mukutra Theory: 
A. Dearrangement in types Vatham 
S.No. Type of Vatham No. of cases % 
1. Piranan 2 5 
2. Abanan 38 95 
3. Viyanan 40 100 
4. Uthanan - - 
5. Samanan 40 100 
6. Naagan - - 
7. Koorman - - 
8. Kirukaran 38 95 
9. Devathathan 40 100 
10 Thananjeyan - - 
 
B. Dearrangement in Pitham 
S.No. Type of Pitham No. of cases % 
1. Analagam 18 45 
2. Ranjakam 35 87 
3. Saathakam 40 100 
4. Prasagam - - 
5. Aalosagam - - 
 
 
 
 
 
C. Dearrangement in types of kabam 
S.No. Type of Kabam No. of cases % 
1. Avalambakam 40 100 
2. Kilethakam 18 45 
3. Pothakam - - 
4. Tharpakam - - 
5. Santhikam 40 100 
 
9. Udal Kattugal 
S.No. Type of Kattugal No. of cases % 
1. Saaram 40 100 
2. Senneer 35 87 
3. Oon 15 62 
4. Kozhuppu 20 50 
5. Enbu 40 100 
6. Moolai 5 12 
7. Sukilam / Suronitham - - 
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10. Envagaithervugal 
S.No. Type of Envagaithervugal No. of cases % 
1. Naa 30 75 
2. Niram 38 95 
3. Mozhi 1 3 
4. Vizhi 30 75 
5. Sparisam 40 100 
6. Naadi 40 100 
7. Malam 30 75 
8. Moothiram 10 22 
 
 
 
11. Naadi 
S.No. Type of Naadi No. of cases % 
1. Vatham 30 75 
2. Pitham 5 12.5 
3. Vatha pitham 5 12.5 
 
 
 
12. Neikuri 
S.No. Character of Neikuri No. of cases % 
1. Spreads like Salladaikan 1 3 
2. Spreads like Pearl 36 90 
3. Spreads in improper shape 3 7 
 
 
 
 
 
 
 
 
 
13. Duration of Illness 
S.No. Duration of Illness No. of cases % 
1. 1 – 3 months 1 2.5 
2. 3 – 6 months 2 5 
3. 6 months – 1 year 4 10 
4. 1 – 3 years 25 62.5 
5. 3 years & above 8 20 
 
14. Onset of disease 
S.No. Mode of Onset No. of cases % 
1. Sudden 5 13 
2. Gradual 35 87 
 
 
 
15. a. Clinical Features 
S.No. Clinical Features No. of cases % 
1. Joint pain 40 100 
2. Swelling 35 87 
3. Morning stiffness 40 100 
4. Restricted movements 35 87 
5. Difficulty in chewing 1 3 
6. Difficulty in walking 30 75 
7. Sleeplessness 20 50 
8. Fever 3 7 
9. Loss of appetite 18 45 
10. Constipation 30 75 
11. Easy Fatigability 25 63 
 
 
 
 
 
15. b. Clinical Features 
S.No. Clinical Features No. of cases % 
1. Subcutaneous nodules 2 5 
2. Muscle wasting - - 
3. Opthalmic manifestation - - 
4. Hepatomegaly - - 
5. Spleenomegaly - - 
6. Anaemia 35 75 
7. Tenderness 40 100 
 
16. a. Involvement of Locometor System 
Table showing involvement extremities. 
S.No. Mode of Onset No. of cases % 
1. Upper extremities 30 75 
2. Lower extremities 3 7 
3. Both extremities 7 18 
 
16. b. Joint Involvement 
S.No. Joint Involvement No. of cases % 
1. Proximal interphalangeal 
joint of hands 
30 75 
2. Metacarpophalangeal joints 38 95 
3. Wrist joint 35 88 
4. Elbow 20 50 
5. Shoulder 2 5 
6. Temperomandibular joint 1 3 
7. Sternocleidomastoid - - 
8. Cervical spine 2 5 
9. Hip joint 6 15 
10. Knee joint 6 15 
 
 
 
 
11. Ankle joint 20 50 
12. Metatarsophalangeal joint 2 5 
 
17. Assocated diseases 
S.No. Associated diseases No. of cases % 
1. Diabetes milletus 1 3 
2. Hypertension - - 
3. Osteo arthritis 2 5 
 
 
18. Grading of Rhumatoid arthritis 
Grade Symptoms 
G I No restriction of ability to perform normal 
activities. 
G II Moderate restriction but with ability to perform 
most of the daily activities 
G III Marked restriction with an inability to perform 
daily activities. 
G IV Incapacitation with confinement to bed. 
 
Grade No of cases % 
I 5 12.5 
II 25 62.5 
III 10 25 
IV - - 
                               
                                 
 
 
 
 
 
 
 
     Grading of Rheumatoid arthritis 
 
 
19. A). ASSESSMENT OF CURATIVE EFFECTS IN RHEUMATOID 
ARTHRITIS PATIENTS TREATED ONLY WITH TRIAL DRUGS: 
SYMPTOMS 
INITIAL READINGS FINAL READINGS 
NO OF PATIENTS PERCENTAGE NO OF PATIENTS PERCENTAGE 
No Pain 0 0 3 15 
Mild 2 10 10 50 
Moderate 12 60 5 25 
Severe 6 30 2 10 
Inference: 
                Among the patients who were selected for treating alone with trial drugs, 
6 of them had severe symptoms, 12 had moderate symptoms, and the remaining 6 
patients had mild symptoms. But after treatment only 3 had severe symptoms, 5 
had moderate symptoms, 10 had mild symptoms and 2 had no clinical 
manifestations. 
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19. A). EFFECT OF TRIAL DRUG ALONE: 
Effect of therapy is assessed from the above tabulated data. 
Effect of the Therapy No. of Patients Percentage 
Good 3 15 
Moderate 10 50 
Mild 
5 
 
25 
No 2 10 
Inference: 
         By treating alone with trial drugs, 15% of patients had good improvement, 
50% of patients had moderate improvement, 25% had mild improvement, and10% 
had no improvement. 
19.B). ASSESSMENT OF CURATIVE EFFECTS IN RHEUMATOID 
ARTHRITIS PATIENTS TREATED WITH TRIAL DRUGS ALONG WITH 
COMPLEMENTARY THERAPIES. 
 
SYMPTOMS 
INITIAL READINGS FINAL READINGS 
NO. OF 
PATIENTS 
PERCENTAGE 
NO. OF 
PATIENTS 
PERCENTAGE 
No Pain 0 0 10 50 
Mild 1 5 6 30 
Moderate 9 45 3 15 
Severe 10 50 1 5 
Inference: 
           Among the patients who were selected for treating both with trial drugs and 
complementary therapies, 10 of them had severe symptoms, 9 had moderate 
symptoms, and the remaining 1 patient had mild symptoms. But after treatment 1 
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had no clinical manifestations, 30 had only mild symptoms and the remaining 3 
had moderate symptoms. 1 case reported to have severe symptoms. 
 
19.B). EFFECT OF TRIAL DRUG ALONG WITH COMPLEMENTARY 
THERAPIES: 
EFFECT OF THERAPY NO. OF PATIENTS PERCENTAGE 
Good 10 50 
Moderate 6 30 
Mild 3 15 
No 1 5 
Inference: 
         By treating both with trial drugs and complementary therapies,50% of 
patients had good improvement, 30% of patients had moderate improvement 
and15 % only had mild improvement.1 person reported to have nil prognosis. 
 
19. COMPARISON BETWEEN EFFECTIVE OF TRIAL DRUG AND 
TRIAL DRUG WITH COMPLEMENTARY THERAPIES: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20. OVERALL RESULTS AFTER TREATMENT: 
   Based on outcome, effects after treatment was classified into 4 grades as 
MARKED EFFECT: 
 No longer any clinical manifestations. 
 Patient could work and live normally. 
 No recurrence after some months. 
MODERATE EFFECT: 
 Moderate reduction of manifestations. 
 Slight pain after movement. 
MILD EFFECT: 
 Slight reduction in the clinical manifestation.  
 With relapse. 
NO EFFECT: 
 
       No reduction of pain and tenderness. 
 
EFFECT OF THERAPY NO. OF CASES PERCENTAGE 
Marked effect 8 20 
Moderate effect 20 50 
Mild effect 10 25 
No effect 2 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
OVERALL RESULTS AFTER TREATMENT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
5
10
15
20
25
30
35
40
45
50
Marked effect Moderate 
effect
Mild effect No effect
Effect of Therapy
PERCENTAGE
 
 
 
 
DISCUSSION 
 
As a pursuit in fulfilling the prime aim of this study the following trial 
drugs for treating the diseases Uthiravathasuronitham were selected 
1. MYELIRAGATHI ENNAI as the internal medicine 
2. VAENGAIPATTAI THYLAM as the external medicine   
 A detailed study of the disease Rheumatoid arthritis was done and was 
correlated to the signs and symptoms of Uthiravathasuronitham mentioned in the 
siddha literatures. 
In order to fulfill the primary objectives of this study, a complete open 
clinical trial was done with the trial drugs in treating the disease 
Uthiravathasuronitham 
 The clinical evaluation was done as per the protocol and the data were 
collected by using prescribed forms. The disease Uthiravathasuronitham was 
studied under various criteria to meet the secondary objectives of the study and the 
results were observed and tabulated. The various criteria and the results were 
discussed here under. 
Gender distribution 
 The inference from the data obtained during the course of the study shows 
the disease more commonly affected the females(90%) than the males(10%).  . 
Age distribution  
 In this study the disaease was more pronounced above 30 years.           
Kaalam distribution 
 The higher incidence (75%) was found to be in pitha kaalam (34-66 years). 
Seasonal variations 
 From the inferred data it is noted that 20 patients were admitted in 
koothirkaalam 10 patients in Kaarkalam and 8 patients in mudhuvenil kalam. 
 Actually the study period for this clinical trial lies between June -2012 to 
January-2013. So the obtained result may not have a scientific value to influence 
the disease and a long period study is required to evaluate the influence of seasonal 
variations. 
 
 
 
 
Thinai reference  
 The obtained result shows that incidence was higher in maruthanilam. 
 As this study is a single centered study the obtained results may not have a 
scientific evolution of influence of living lands on osteoarthritis so a thorough 
multicenter study in wide spread areas are needed to evaluate it. 
Socio -economic status 
 Here 25% were reported to be poor and 65% cases were from middle class 
and the remaining 10% were rich.  
Dietary habits  
 38 patients were reported to have non-vegetarian diet. So this data has no 
statistically significant data. 
Mode of onset: 
 According to this study 87% of cases were reported to have a  gradual onset 
of disease. 13% of them reported to have a sudden onset. 
Clinical features 
 From the tabulated data, it was clear that majority of the patients had joint 
pains(100%),swelling(87%), morning stiffness(100%),restricted movement(87%) 
as their predominating symptoms. 
Distribution of Three Thodams 
a) Vatham: 
Samanan ,viyanan,devatathan were found to be affected in all the 40 
patients.Abanan was affected in 38 patients. 
b) Pitham: 
Saathagam was affected in all the 40 cases.Ranjagam was affected in 35 
patients. 
c) Kabam: 
 In all the cases santhigam  and avalambagam was found to be affected was 
affected in all cases. 
Udal Kattugal: Among the 40 cases Enbu and Saaram were affected in 100% of 
cases, Senneer 87% Oon 62% Kozhuppu 50% moolai 5% were affected 
respectively. 
 
 
 
 
Ennvagai thervugal: 
 Almost all the thervugal showed modified results. .  
Limbs 
 It is noted that the disease predominently affected the upper limb 75% 
comparitively to lower limb 7% and both the limbs were affected in 18%. 
Naadi 
 About 40 cases treated, 75 % had Vaatha Naadi affected. 
Neikuri 
 90% of patients neikuri spreaded like Pearl. One 17 year old girl patient 
neikuri presented with Salladaikan. 
Joints 
 75% of patients had upper limb deformities. 
 95% of patients had Metacarpophalangeal joint involvement. 
 75% of patients had Proximal interphalangeal joint involvement. 
 88% of patients had Wrist joint involvement. 
 3% of the patient with Temperomandibular joint involvement. 
            Laboratory investigations were done for all the cases before and after 
treatment. There were no significant variations in the laboratory investigation 
except in certain parameters like ESR and Hb.Although there is no  investigations 
supporting the progress  50% of the patients where relieved from their symptoms 
which is evaluated clinically….  
 The phytochemical analysis of Myeliragathi ennai  had shown the presence 
of calcium, sulphate, unsaturated compounds, reducing sugar and amino acid. 
 Pharmacological studies of Myeliragathi ennai  show significant analgesic, 
acute anti inflammatory and moderate chronic anti inflammatory, Antipyretic  
actions. Vaengaipattai thylam had moderate acute-anti inflammatory action. 
Treatment 
 In siddha system of medicine the line of treatment primarily aimed to retain 
the deranged thodams and then providing relief from symptoms so before 
treatment each patient was advised for purgation by giving Sithathi ennai with 
neerakaaram during morning for first day treatment. 
 
 
 
 
 From the second day onwards Internal medicine – MYELIRAGATHI  
ENNAI-4ml with inji juice for two times a day. 
 External medicine –VAENGAIPATTAI THYLAM were given. 
 During treatment, the patients were advised to follow pathiyam (avoid 
tamarind, tubers etc) and particularly advised to avoid foods which increases 
vatham. 
 Along the course of the treatment, some of the complementary therapies 
which were already planned for the comparison of effects like ottradam, varma 
adangal thadaval, mutthirai, asana, steam bath were given additionally to some of 
the patients. 
 The outcome is mainly assessed by reduction in severity of Joint pain, 
Stiffness and improvement in physical functioning and quality of life. Universal 
pain assessment scale  used to infer proper outcomes. 
 No adverse effect of both internal and external medicine was noted along 
the course of the treatment clinically.  
  
 
 
 
 
SUMMARY 
 The disease Uthiravathasuroitham was comparatively studied with the 
disease Rheumatoid arthritis with reference to its etiology, pathogenesis and 
clinical features. Rheumatoid arthritis is the leading cause of chronic disability and 
permanent deformities in the 0.5%-1% population and only symptomatic relief is 
found. There is a need to evaluate the safe and effective drug for Rheumatoid 
arthritis. So SITHATHI ENNAI is given for purgation during the initiation of the 
treatment; Then      MYELIRAGATHI ENNAI as internal medicine and 
VAENGAIPATTAI THYLAM as external medicine was selected and a clinical 
trial in Govt. Siddha Medical College, Palayamkottai was conducted with these 
drugs. For this 40 cases were selected in which12 were treated in OutPatient ward 
and remaining 28 in InPatient ward. The pre clinical studies of the trial drug were 
found to be encouraging. 
 Pharmacological analysis of Myeliragathi ennail shows 
 significant analgesic action 
 moderate Acute anti inflammatory action 
 significant chronic anti inflammatory action.                          
 Moderate antipyretic action 
Pharmacological analysis of Vaengaipattai thylam shows 
 Moderate acute anti inflammatory action 
The diagnosing criteria mainly Morning stiffness in joints, involvement of 
metacarpophalangeal joints, Joint pain (+), Swelling (+) are noted for the clinical 
assesment of the prognosis. 
The efficacy of medicine studied during the course of the research work. 
• Pain is reduced 
• Swelling & Warmth is reduced 
• Morning stiffness is reduced 
• Patients where able to perform their daily activities with comfort. Fever is 
not found, in some cases with the episodes of fever periodically  is also 
controlled. 
 
 
 
 
Since complementary therapies or manual therapies like massage, 
fomentation, exercises plays a significant role in treating 
UTHIRAVATHASURONITHAM some of the complementary therapies from 
siddha system are manipulated along with trial drugs depending upon the severity 
of the disease. 
Daily progress was observed to evaluate the efficacy. The results obtained 
were found to be auspicious. Particularly results by complementary therapies were 
found to be very auspicious. 
No adverse reactions were found. Hence the trial drug was found to be safe 
and effective. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
In this clinical study with SITHATHI ENNAI to balance the humors 
(vali,azal,iyam), the trial drugs “MYELIRAGATHI ENNAI” and 
“VAENGAIPATTAI THYLAM” were taken as Internal & External drug 
respectively for treating the disease UTHIRAVATHASURONITHAM.   
In the pre clinical study Pharmacological evaluation of the trial drugs shows 
 Significant analgesic effect 
 Significant acute anti inflammatory effect 
 Moderate Antipyretic action. 
During the initiation of the clinical study, SITHATHI ENNAI 
administration in all the UTHIRAVATHASURONITHAM patients showed 
miraculous progress in the patients .it also supported the further treatment 
too.        
The Overall results of  efficacy of the trial drugs supported by the 
complementary therapies played an important role in  reducing the clinical 
signs and symptoms like  Joint pain, swelling, morning stiffness,movement 
restriction  in this Clinical study were  found to have marked effect in 20% 
cases, Moderate effect in 50 % cases, Mild in 25 % cases and no effect in 5% 
cases.  
The costs of the trial medicines were relatively economical. The raw drugs 
are easily available and the preparation was also convenient. No adverse effects 
and side effects were found clinically for the trial drugs. So the clinical effect of 
the trial drugs along with complementary therapies was found to be Moderate in 
treating the disease Uthiravathasuronitham (Rheumatoid arthritis). 
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Preparation & properties of drugs 
Annexure – I  
STANDARD OPERATING PROCEDURE FOR PREPARATION OF  
SOURCE OF RAW DRUGS: 
           The required drugs for preparation of (Internal)  and  (External)  are 
purchased from a well reputed country shop and Raw drugs are Authenticated by 
Medical botanist of Govt. Siddha Medical College, Palayamkottai, then  purified 
and the  medicines are prepared in the  Gunapadam laboratory of Govt. Siddha 
Medical College, Palayamkottai. 
INGREDIENTS: 
INTERNAL MEDICINE:        MYLERAGATHI  ENNAI  
1. Vembu Ennai (Neem oil) – 2.7litres. 
2. Myleragu -560gms         
(A Group) Kalkam Ingredients : 
 a. Jathikoshtam(Costus igneus)-8g   
 b. Kattujeerakam(Centratherum anthelminticum)-8g 
 c. Akarakaram (Anacyclus pyrethrum)-8g    
 d. Milakoi vatral(Capsicum annum)-8g 
 e. Vellaipoondu (Allium sativum )-8g    
 f. Kasthuri manjal(Curcuma aromatica )-8g 
 g. Karunjeerakam(Nigella sativa)-8g    
 h. Kalarchiparuppu(Caesalpinia crista).-8g 
(B group) Medicines Are : 
a. Purified Rasakarpuram (finely powdered)-8g 
b. Purified Jathilingam (finely powdered)-8g 
c. Purified Manosilai (finely powdered)-8g 
d. Karpura silasathu baspam (finely powdered)-8g 
e. Purified Ghendakam (finely powdered)-8g 
f. Nattu Soodan (finely powdered)-8g 
 
 
 
 
 
 
Method of Preparation  
 Myleragu is cut into small bits, placed in a thailam boiling vessel on fire, 
surred and when it is melted it becomes completely blackened. The Vembu ennai 
is then poured in it and the following kalkam ingredients under group (a) are added 
to the oil in the manner mentioned below. 
 A Group ingredients in equal parts (of each 16 p.w. or 2 oz each) are taken, 
rubbed into a fine kalkam by using Inji about 175 gms and vertilai juice about 175 
gms and mixed with the oil. At the same time KUPPAIMENI LEAVES about a 
coconut size rubbed into a kalkam is added to the oil. Now the oil is allowed to 
boil on slow fire and when thailam pakam (karapakam) is reached, the thailam is 
decanted in a Vadikadam.  
 B Group ingredients are taken in equal parts (of each 16 p.w. or 2 oz each) 
powdered individually, put in the Vadikadam (receiver) while the above thailam is 
being decanted, filtered, stirred well, allowed to cool itself and then bottled up in 
wide mouthed glass jars. Every time it is used it should be stirred well or shaken 
well before use.  
  Dose: ½ to 1 or 1 ½ teaspoonful for adults and 10 to 30 drops for children 
according to their age and nature of constitution may be given with cow’s milk or 
breast milk or orange juice or Inji juice and honey or any other suitable decoctions 
twice a day for a course of 3 ½ to 5 days or even seven days in severe cases.  
EXTERNAL MEDICINE VAENGAIPATTAI THYLAM 
 1.  Vaengaipattai - 350 gm 
 2.  Gingelly Oil - 2 Litres 
 3. Vilamichu Vaer - 35 gms 
 4. Milagu  - 35 gms 
 5. Vaelulli  - 35 gms 
 6. Nar Seeragam - 35 gms 
METHOD OF PREPARATION 
 Vaengaipattai is cut into pieces. To it 8 parts of water is added and fired till 
it is reduced to 1 part. To the Vaengaipattai thylam decotion Gingelly oil is added 
and again fired. Vilamichu vaer, Milagu, Vellulli, Narseeragam is pawdered & 
 
 
 
 
added along with it. It is stirred well till thylampagam comes and then filtered & 
bottled up.  
 
 
 
 
PREPARATION AND PROPERTIES OF TRIAL DRUG 
 
1. Mylerageu 
 Name : PAVO CRISTATUS (Peacock) 
 Part used : Feather 
 Other names :  rpfp> Qkyp> Njhif> rpfz;b> kQ;iQ> kA+uk;> 
gPyp> etpuk;> ruzk;> Rfz;lk;> $e;jy;> re;jpud; 
fyhgd;> $io> njhq;fy;> J}tp. 
   
 Purification  : kapypwif Rl;L rhk;gyhf;Fjy;.  
 bghJ Fzk; : nrk;G rj;J ,Uf;fpwJ.  
 
2. Neem Oil 
 Name : Azadirachta indica 
 Part used : Oil from seeds. 
 Other names : mhpl;lk;> Jj;ij> epk;gk;> ghhpgj;jpuk;> gpRke;jk;> 
thjhhp.  
 Habit : Tree 
 Rit : ifg;G 
 jd;ik : ntg;gk; 
 gphpT : fhHg;G 
 nghJ Fzk;:  thjk; Nghk; gpj;jkpFk; khwhf;fp uj;jpnahL 
   NkhJfug; ghd;rpuq;F Kd;dprpTk;-XJlypd; 
   ehg;g ZWRuK ehL rd;dp Ae;njhiyAk; 
    Ntg;gnea; nad;nwhUf;fhy; tps;S.  
Chemical constituents: 
Azadirachtin, azadiradione, fraxinellone, nimbin, solannin, solannol, 
numbidin, numbicidine, tannin, flavanoides, numbinol, acidin-anti flammatory, 
anti arthritic, anti pyretic, anti bacterial, anti fungal 
 
 
 
 
 
 
3. Nfhl;lk;:  
 Name : Costus Speciosus 
 Part used : Root 
 Other names : Fuh> xyp 
 Habit : Climber 
 Rit : ifg;G> tpWtpWg;G 
 jd;ik : ntg;gk; 
 gphpT : fhHg;G 
 Purification : tWj;J nghbj;J vLj;Jf; nfhs;sy;. 
 nghJ Fzk;: ehl;bYW ntl;il eLf;fk; vDNeha;fs; 
Nfhl;lnkdr; nrhd;dhy; FiyAq;fhz; - 
$l;bw; RuNjhle; njhz;il Neha; Njhyhj 
gpj;jk; guNjrk; NghNk gwe;J  
 
Chemical constituents: 
Diosgenin, prosapogenin B, diosgenone, cycloartanol, octacosanoic acid, 
25-en-cycloartenol 
 
4. fhl;L rPufk; 
 Name : Centratherum anthelminticum 
 Part used : Seeds / Fruits 
 Other names : mir/ rPhp/ cgFk;ggPrk;/ ew;rPhp/ 
Jj;jrhk;gyk;/ gpj;jehrpdp/ 
   nghrdFnlhhp 
 Rit : fhh;g;g[/ ,dpg;g[ 
 jd;ik : jl;gk; 
 gphpt[ : ,dpg;g[ 
 Purification : tWj;J bghoj;J vLj;Jf; bfhs;sy; 
 bghJ Fzk; : tha[bthU ehrpneha; td;gpj;j+; nruhJ 
   fhak; befpHhJ fz;FspUe; ? J}akyh;f; 
   fhusfg; bgz;kapny- iffz;l jpj;jida[+; 
   rPufj;ij ePjpdKe; jpd; 
 
 
 
 
 
 
5. mf;fufhuk;  
 Name : Anacyclus Pyrethrum 
 Part used : Root 
 Other names : mf;fpuhfhuk;mf;fpuhfhuk; 
 Rit : fhHg;G 
 jd;ik  : ntg;gk; 
 gphpT : fhHg;G  
 Purification : tWj;J nghbj;J vLj;Jf; nfhs;sy; 
 nghJ Fzk;:  mf;fufhuk; mjd;NgH ciuj;jf; fhy; 
cf;fpufhy; mj;Njhlk; XLq;fhz;-Kf;fpakha;f; 
nfhz;lhy; ryk;CWk; nfhk;gidNa-  jhfRuk; 
fz;lhy; gae;NjhLk; fhz;. 
Chemical constituents: 
Essential oil, Alkaloid pellitorin or perethrin, lignane, sesamine, inulin 
deca-2, 4-deln acid-isobutylamide, anacycline 
 
6. kpsfha; tw;wy;:  
 Name : Capsicum annum 
 Parts used : Fruit (dried) 
 Other names : Ksfha; 
 Rit : fhh;g ;G 
 jd;ik : ntg;gk; 
 gphpT : fhh;g ;G 
 nghJ Fzk; : %y tpuj;j Kisf;fLg;G cz;lhFe; jhykjpy; 
jhJ jiof;Fk; nkd;gH - MynkDk; ke;jk; 
mNuhrpFd;kk; tha;Tk; nghUkYk; Nghk; ce;J 
kps fha;g;goj;jhy; xJ  
Chemical constituents: 
Capsanthin, capsanthin 5, 6 epoxide, capsorubin, provitamin A, zea xanthin, 
violaxanthin, B carotene 
 
 
 
 
 
7. nts;is G+z;L 
 Name : Allium Sativum 
 Part used : Tuber 
 Other names : ,yRdk;> fhak;> cs;sp> nts;tq;fhak;  
 Rit : fhh;g ;G 
 jd;ik : ntg;gk; 
 gphpT : fhh;g ;G 
 Purification : NjhYhpj;J vLj;Jf; nfhs;sy;  
 nghJ Fzk;: rd;dpnahL thje; jiyNehT jhs;typ 
kd;dptU ePHf;Nfhit td;rPjk; - md;dNk- 
cs;Ss;sp fz;gha; cis%y NuhfKk; 
Nghk;nts;Ss;sp jd;dhy;ntUz;L  
 
Chemical constituents: 
Premethane thio sulfonate, diallyl sulbide, diallyl trisulfide, B spirostanol buteolin 
 
8. fj;J}hp kQ;rs; 
 Name : Curcuma aromatica 
 Part used : Root 
 Rit : ifg;G 
 jd;ik : ntg;gk; 
 gphpT : fhh;g ;G 
 nghJ Fzk;: Gz;Zq; fug;ghDk; Nghfhf; fpUkpfSk; 
ez;Zke; jhf;fpdpA ehrkhk; - tz;zkyHj; 
njhj;Nj wsfkpd;Nd- Rf;fpyKk; GjpAkhq; 
    fj;J}hp kQ;rSf;Ff; fhz;  
Chemical constituents: 
Curcuminoides diarylheptanoids, curcumin, demethoxycurcumin, curcumol, 
eelemicin, curdione neocurdione 
 
 
 
 
 
 
9. fUQ;rPufk; 
 Name : Nigella Sativa 
 Part used : Seeds 
 Other names : muzk;> cgFQ;rpif  
 Rit : ifg;G 
 jd;ik : ntg;gk; 
 gphpT : fhh;g ;G 
 Purification : tWj;J nghbj;J vLj;Jf; nfhs;sy;  
 nghJ Fzk;: fUQ;rP ufj;jhd; fug;gndhL Gz;Zk; 
tUQ;rpuha;g; g PerK khw;Wk; - mUe;jpdhy; 
fha;r;ry; jiytypAq; fz;typAk; NghKyfpy; 
tha;r;r kUe;njNt it.  
Chemical constituents: 
Curcuminoides diarylheptanoids, curcumin, demethoxycurcumin, curcumol, 
eelemicin, curdione neocurdione. 
 
10. fow;rp gUg;G 
 Name : Caesalpina crista 
 Part used : Seeds 
 Other names : t[;[pugP[k;> fow;fha;> fr;rf;fha;> FNguhl;rp  
 Habits : Climber 
 Rit : ifg;G 
 jd;ik : ntg;gk; 
 gphpT : fhh;g ;G 
 nghJ Fzk;: tpiuthje; #iyaWk; ntl;ilnad NyFk; 
epiuNrHe;j Fd;kk; epiyah - JiuNrH mow;rp 
tpyFk; mUe;jpw; frg;ghq; fow;rpapiy 
nad;Wiuf;Fq; fhy;  
Chemical constituents: 
Caesalpin, bonducin, fatty acid, glycerol, norcassane-type diterpenes, nor 
caesalpinin AB and C 
 
 
 
 
 
11. ,urf;fw;G+uk; 
 Name : Hydragyrum subchloride 
 Rit : cg;G> fhHg;G 
 jd;ik : ntg;gk; 
 gphpT : fhh;g ;G 
 Rj;jp : ntw;wpiy kpsF ,uz;ilAk; miuj;J 
fw;fkhf;fTk;. ePhpy; fye;J mLg;Ngw;wTk;. 
G+uj;ij fpopfl;b ntw;wpiy ntw;wpiy kpsF 
FbePhpy; 3 kzpNeuk; vLf;f Rj;jpahFk;.  
 nghJ Fzk; : ‘,ilthj #iy nahp#iy Fd;ke; 
njhilthio thjkhQ; Nrhzp- apilahNjh 
nthf;Fur fHg;G+u nkhd;Nw asnthLey; 
,f;Fnty;yj; NjOeh sP” 
 
12. ,ypq;fk; 
 Name : Red sulphide of mercury 
 Other names : ,q;Fypfk;> filtd;dpfHg;gk;> fypf;fk;> 
fhQ;rdk;> fhuzk;> fz;lfk;> rkurk;> 
nre;J}uk;> tdp> td;dp> kzpuhfk;> kpNyr;rk; 
 jd;ik : ntg;gk; 
 Rj;jp : ,ypq;fj;jpw;F %d;W kzp Neuk; ghy;> 
Fg;igNkdp rhW> gor;rhw;why; RUf;F 
nfhLf;fTk;. 
 nghJ Fzk; : Ngjp RuQ; rd;dp ngUtpuz  
  ePnuhLj fhjfb fhrq; fug;ghd;Gz; - Nzhj  
  TUtpypq;f rq;fjkh A+Wfl;b Ak;Nghq; 
   FUtpypq;f rq;fkj;ijf; nfhs;    
    
 
  
 
 
 
 
 
 ‘MjpapujTUf; fhjyhw; rhjpypq;f 
 Nkhjp ypujFz Kw;Wlypw; - wPJGhp Fl;lq;  
 fpue;jp nfhLQ;#iy thjKj  
 Yl;lq;F Neha;fisNahl; Lk;”  
 
13. kNdhrpiy  
 Name : Red Orpiment  
 Rj;jp : kNdhrpiyia gor;rhW Nrh;j;J 3 kzp Neuk; 
miuj;J vLf;f Rj;jpahFk;. 
nghJf;Fzk; : nfhba F\;lk; fha;r;ry; eLf;fy[ fy;ypapiug 
Gr;rpye;jpg; NgrWk Ndhrpiyf;Fg; NgR.” 
 
14. rpyhre;J gw;gk; 
 Rj;jp : Rz;zhk;G. GePW fye;j ePhpy; 3 kzp Neuk; 
vhpj;J vLj;Jf; nfhs;s Rj;jpahFk;. 
nghJ Fzk; : ‘fy;yilg;G Nkfa; fdJ}y; tpj;jpujp 
   nrhy;yilf;F ePuUWfw; Nrhzpjf;fhd;- 
        nky;ypilahh;f;  
   fpy;yfr;rj; jpy;iynaD kpe;jphpa el;lKkhq; 
fy;yfr;rj; jpy;iynaDq;fhy;.” 
 
15. fe;jfk; 
 Name : Sulphur 
 Rit : ifg;G> Jth;g;G 
 Rj;jp : fe;jfj;ij ntz;nza; Nrh;j;J cUf;fp 
gRk;ghypy; 7 Kiw fha;f;fTk;. 
nghJ Fzk; : ney;ypf;fha; fe;jpf;F ePs;gjpndz; Fl;lke;jk; 
ty;iy ftpirFd;k thAfz;Nzha; - nghy;yh 
tplf;fbtd; NkfNeha; tPWRuk; Ngjp  
   jplf;fpuR zPfgk;Nghe; Njh; 
 
 
 
 
 
16. ehl;L #ld; 
 Name : Camphor 
 Rit : tpWtpWg;Gld; $ba ifg;Gk> ; fhh;g ;Gk; 
 tPhpak; : ntg;gk; 
 gphpT : fhh;g ;G 
 nghJ Fzk; : fpUkpry njhlq; fpistypg;G re;ep 
   nghUKke;jk; mq;fpgl;l Gz;Nzh -
nlhpRuq;fs; 
   the;jpgpj;jq; rPjKW thjq; nrtpKfNeha; 
   fhe;jpjUk; G+unkhd;whw; rhw;W. 
 
 Properties of Drugs in Vaengaipattai Thylam 
1. Ntq;ifg;gl;il 
 Name : Pterocarpus marsupium 
 Part used : Bark 
 Other names : mrdk;> fzp> jpkpR> gpurhuk; 
 Habit : Tree 
 Rit : Jth;g;G 
 jd;ik : jl;gk; 
 gphpT : ,dpg;G 
 nghJ Fzk; : gf;Ftkh ahW gjj;ij tijj;Jlypy; 
   kpf;f gpzpia tpul;bAg; - Gf;fy; 
   kzpapuj Nkhf tijfisg; ge;jpf;Fq; 
   fzpajid ed;wha;f; fzp 
2. tpyhkpr;R 
 Name : Coleus Vetiveroides 
 Part used : Root 
 Habit : Herb 
 Rit : ifg;G 
 jd;ik : rPjk; 
 
 
 
 
 gphpT : ,dpg;G 
 nghJ Fzk; : Nkfk; tpopnahpr;ry; tPwpuj;j gpj;jbkhL 
   jhfkj %h;r;irgpj;je; jd;kaf;fk; - NrhfQ; 
   rpuNeha; ,itnaFQ; nra;atpyh kpr;Rf; 
   nfhpRuKk; ,y;iy apir. 
3. kpsF 
 Name : Piper nigrum 
 Part used : Fruit 
 Habit : Climber 
 Other names : fypid> fwp> fhak;> Nfhsfk;> jpuq;fy;> kphpay;> 
rUkge;jk;> ts;sprk;> khrk;> FWkpsF> 
kiyahsp 
 Rit : ifg;G> fhh;g ;G 
 jd;ik : ntg;gk; 
 gphpT : fhh;g ;G 
 nghJ Fzk; : msitAwhf;fhuk; mile;jpUf;Fk; thj 
tpisitnay; yhkWf;Fk; nka;na-kpsfpd;fha;  
   fz;lth;f;Fk; ,d;gkhk; fhhpifNa- rPo;%yq; 
nfhz;lth;f;Fk; ed;kUe;jhq; $W. 
Chemical constituents: 
Piperine, isopiperolein B, pipercide, pellitorine, dehydropipernonaline, 
isopiperolein. 
 
  
 
 
 
 
Bio – chemical analysis 
ANNEXURE - II 
GOVT SIDDHA MEDICAL COLLEGE- PALAYAMKOTTAI 
BIO – CHEMICAL ANALYSIS OF MYELIRAGATHI ENNAI                                                   
PREPARATION OF THE EXTRACT: 
5gms of the drug was weighed accurately and placed in a 250ml clean 
beaker.  Then 50ml of distilled water added to it and dissolved well.  Then it was 
boiled well for about 10 minutes. It was cooled and filtered in a 100ml volumetric 
flask and then it is made up to 100ml with distilled water.  This fluid was taken for 
analysis. 
 
Qualitative Analysis 
 
S.No. Experiment Observation Inference 
1. Test for calcium 
2ml of the above prepared extract is 
taken in a clean test tube.  To this add 
2 ml of 4% ammonium oxalate 
solution. 
white 
precipitate is 
formed. 
Indicates the 
presence of 
calcium. 
2. Test for sulphate: 
2ml of the extract is added to 5% 
barium chloride solution. 
 white 
precipitate is 
formed. 
Indicates the 
presencee of   
sulphate. 
3. Test for chloride 
The extract is treated with silver 
nitrate solution. 
A white 
precipitate is 
formed. 
Indicates the 
presence of 
chloride. 
4. Test for carbonate 
The substance is treated with 
concentrated HCl. 
No brisk 
effervescence 
is formed. 
Absence of 
carbonate. 
 
 
 
 
5. Test for Starch 
The extract is added with potassium 
ferro cyanide. 
No  colour is 
formed 
Absence of  
Starch 
6. Test for iron Ferric 
The extract is treated with 
concentrated glacial acetic acid and 
potassium ferro cyanide. 
No blue 
colour is 
formed. 
Absence of ferric 
iron. 
7. Test for iron Ferrous: 
The extract is treated with 
concentrated nitric acid and 
ammonium thio cyanate. 
Blood red 
colour is 
formed. 
Indicates 
presence of 
ferrous iron. 
8. Test for phosphate 
The extract is treated with ammonium 
molybdate and concentrated nitric 
acid. 
No Yellow 
precipitate is 
formed. 
Indicates the 
Absence of 
phosphate. 
9. Test for albumin 
The extract is treated with Esbach’s 
reagent. 
No yellow 
precipitate is 
formed. 
Absence of 
albumin. 
10. Test for Tannic acid 
The extract is treated with ferric 
chloride reagent. 
No blue black 
precipitate  is 
formed 
 Absence of  
Tannic acid 
11. Test for unsaturation 
Potassium permanganate solution is 
added to the extract. 
It gets 
decolorized. 
Indicates the 
presence of 
unsaturated 
compound. 
 
 
 
 
12. Test for the reducing sugar 
5ml of benedict’s qualitative solution 
is taken in a test tube and allowed to 
boil for 2 mts and added 8-10 drops of 
the extract and again boil it for 2 mts. 
Colour change 
occurs. 
Indicate the 
presence of 
reducing sugar 
13. Test for amino acid: 
One or two drops of the extract are 
placed on a filter paper and dried it 
well. After drying, 1% ninhydrin is 
sprayed over the same and dried it 
well. 
Violet colour 
is formed. 
Indicates the 
presence of 
Amino acid. 
 
 
14. Test for zinc: 
The extract is treated with potassium 
ferrocyanide 
No white 
precipitated 
Absence of zinc 
Result: 
The trial drug Myeliragathi ennaicontains 
 
Calcium, chloride, Ferrous iron, sulphate, Unsaturated compound, 
Reducing sugar, Amino acid 
 
 
 
 
 
 
 
 
 
 
Pharmacological analysis 
ANNEXURE – III 
GOVT SIDDHA MEDICAL COLLEGE- PALAYAMKOTTAI 
PHARMACOLOGICAL ANALYSIS  
ANALGESIC STUDY OF MYELIRAGATHI ENNAI  
(Internal drug)Aim: 
 To study the analgesic effect on albino rats by tail flick method. 
Preparation of the test Drug: 
            1 gram of  Myeliragathi ennai was suspended in 10ml of Hot 
Water as suspending agent. This 1 ml contained 100mg of the test drug. 
Procedure: 
                 Nine Male Healthy albino rats (weighing 80-100gms) were used for this 
study. The animals were allowed, free access to food and water until they brought 
for the experiment. The animals which showed the positive response to the 
stimulus (within a given time) were selected for the study. After the selection of 
animals which were responding to stimulus within 2 seconds, they were divided 
into three groups, each group consisting of three rats. 
                 The hot water was maintained at 55°C. The tip of the tail was immersed 
into the water bath and the time was noted when the rat flicked the tail. First group 
was given 1ml of water and kept as control. Second group was administered with 
paracetamol at a dose of 20mg/100gm of body weight. Third group as given the 
dose of 100mg/100gm body weight of the animal .After the drug administration, 
the reaction time of each rat after half an hour and one hour were noted in each 
group (when a rat fails to flick the tail, it should not be continued beyond 8 
seconds to avoid injury) and the average was calculated. 
The results of control group, standard group and drug treated group were tabulated 
and compared. 
 
  
 
 
 
 
Study of Analgesic effect of using the drug of Myeliragathi Ennai 
 
Serial 
No 
Name of  
Drug / 
Groups 
Dose / 
100 
gram 
body 
weight 
Initial 
Reading 
After Drug 
administration 
Mean 
Difference 1½ hr 
Average 
1 hr 
Average 
1. 
Control 
(water) 
 
2 ml 
 
20 secs 20 secs 20 secs 20 secs 
 
2. 
 
Standard 
(Paracetamol) 
 
20 mg 
 
2.5 secs 4.5 secs 6.5 secs 6.5 secs 
 
3. 
 
Drug 100 mg 2.5 secs 40 secs 5.0 secs 5.0 secs 
 
Inference: 
                The trial drug had significant analgesic action. 
  
 
 
 
 
STUDY OF ACUTE ANTI – INFLAMMATORY ACTIVITY IN RATS 
USING THE DRUG MYELIRAGATHI ENNAI 
BY HIND – PAW METHOD 
 
Aim: 
 To demonstrate the acute anti-inflammatory activity of Myeliragathi ennai 
in albino rats by Hind-paw method. 
 
Procedure: 
 Nine healthy albino rats weighing 100-150 gm were taken and divided into 
three groups, each consisting of three rats. 
First group was kept as control by giving distilled water orally 2ml/100gm 
body weight. The second group was given ibuprofen at a dose of 20mg /100gm 
body weight. The third group received the test drug at a dose 100mg /100g body 
weight. 
Before administration of test drug, the hind-paw volumes of all rats were 
measured. This was done by dipping the hind-paw upto the tibio-tarsal junction 
into a mercury plethysmograph. While dipping the hind-paw, by pulling the 
syringe piston, the level of mercury in the centre small tube was made to coincide 
with red marking and reading was noted from the plethysmograph. 
Soon after measurement, the drugs were administered orally. One hour 
later, a sub-cutaneous injection of 0.1ml of 1% (W/V) Carrageenan in water was 
made into plantar surface of both hind-paws of each rat. Three hours after 
carrageenan injection, the hind paw volume was measured once again. The 
difference between the initial and final volume was calculated and compared. This 
method is more suitable for studying the anti-inflammatory activity in acute 
inflammation. The values are tabulated. 
 
 
 
 
 
 
 
Study of Acute Anti-Inflammatory activities of MYELIRAGATHI ENNAI by 
Hind Paw Method 
Using plethysemograph using the drug on Myeliragathi Ennai (Internal) 
Serial 
No 
Name of  
Drug / 
Groups 
Dose / 
100 
gram 
body 
weight 
Initial 
Reading 
Average 
Final 
Reading 
Average 
Mean 
Difference 
Percentage 
Inflammation 
Percentage 
Inhibitition 
Remarks 
1. 
Control 
(water) 
 
1  ml 
 
0.55 1.4 0.85 100 - 
 
 
2. 
 
Standar
d (Ibu 
Brufen) 
 
 
20 
mg 
 
0.55 0.75 0.20 23.5 76.5 
 
3. 
 
Uthirav
atha 
Suronith
am 
 
100 
mg 
0.7 1.1 0.4 47.0 53.0 
 
 
Inference: The drug has significant acute anti-inflammatory action. 
 
 
 
 
 
 
ANTI-PYRETIC STUDY OF MYELIRAGATHI ENNAI FOR 
UTHIRAVATHASURONITHAM (RHEUMATOID ARTHRITIS)  
(By yeast induced method) 
Aim: 
 To study the anti pyretic activity of Myeliragathi ennai. 
Procedure: 
 Group of six albino rats were selected and divided equally into 3 groups.  
All the rats were made hyperthermic by subcutaneous injection of 12% 
suspension of yeast at a dose of 1 ml/100 gm of body weight. 
 
 10 hours later one group of animals received only distilled water at a dose 
of 2ml. Second group received standard drug paracetamol 20 mg/ml and the 
third group received the test drug by gastric tube at a dose of  250 mg/ml.  
 Then mean rectal temperature for the 3 groups were recorded at                   
0 hour. 1 ½ hours, 3 hours and 4 ½ hours after the drug administration.  The 
different between the mean temperature of the control group and that of the 
other groups was measured. 
  
 
  
 
 
 
 
ANTI-PYRETIC STUDY OF MYELIRAGATHI ENNAI FOR 
UTHIRAVATHASURONITHAM (RHEUMATOID ARTHRITIS)  
(By yeast induced method) 
TABULATION OF RESULTS OBTAINED 
Sl.
No 
Name of 
the drugs/ 
groups 
Dose/ 
100gm  
body 
weight 
Initial 
temperature in 
centigrade 
After drug administration Remarks 
1 ½ hr 
Average 
3 hr 
Average 
4 ½  hr 
Average Significant 
Action 
1 
Control 
(water) 
2 ml 
37.5 
37.5 
38.0 
38.0 
38.5 
38.5 
38.5 
38.5 
2 
Standard 
Paracetam
ol 
20mg 
37.0 
37.0 
36.0 
36.0 
 
35.0 
35.0 
 
34.0 
34.0 
 
3. 
Myeliraga
thi ennai 
2 ml 
37.0 
37.0 
36.2 
36.0 
35.3  
35.0 
34.5  
34.5 
 
Inference:  
Myeliragathi ennai has significant antipyretic action.  
  
 
 
 
 
ACUTE ANTI - INFLAMMATORY STUDY ON VAENGAIPATTAI  
THYLAM(EXTERNAL USE)  
BY HIND-PAW METHOD IN ALBINO RATS 
Aim: 
 To study the acute anti-inflammatory activity of the test drug 
VAENGAIPATTAI THYLAM as per the preparation given in 
ATHMARATCHAMIRTHAM 
Procedure: 
Nine healthy albino rats weighing 100-150gm were taken and divided into 
three groups, each consisting of 3 rats. 
First group was kept as control by giving distilled water of 2ml/100gm of 
body weight. The second group was kept as test group. The third group was given 
the standard drug. 
Before application of the test drug the Hind-paw volume of all the rats 
were measured. This was done by dipping the Hind-paw up to the tibio-
femoral junction into a mercury plethysmograph. While dipping the Hind-paw, 
by pulling the syringe piston, the level of mercury in the centre small tube was 
made to coincide with red marking and reading was noted from the 
plethysmograph. 
One hour later, a sub-cutaneous injection of 0.1ml of l %( w/r)  
Carrageenan water made into plantar surface of both Hind-paw of each rat. To 
the second (last) group Vaengaipattai thylam was topically applied for three 
times over the inflammed surface in a thin layer for every 15mts for an hour. 
To the contol group no drug was applied over the inflammed surface. To the 
standard group the standard drug Ibuprofen in a dose of 20mg/100gm body weight 
was given. 
Three hour after injection the Hind-paw volume was measured once again.  The 
difference between the initial and final volume would show the amount of 
inflammation.  Taking the volume in the control group as 100% of inflammation, 
anti – inflammatory effect of the test group is calculated.    
 
 
 
 
 
Study of Acute Anti-Inflammatory by Hind Paw Method 
Using plethysemograph using the drug on Vaengai Pattai Thylam 
Serial 
No 
Name of  
Drug / 
Groups 
Dose / 
100 
gram 
body 
weight 
Initial 
Reading 
Average 
Final 
Reading 
Average 
Mean 
Difference 
Percentage 
Inflammation 
Percentage 
Inhibitition 
Remarks 
1. 
Control 
(water) 
 
2   ml 
 
0.55 1.4 0.85 100 - 
 
2. 
 
Standard 
(Ibu 
Brufen) 
 
 
20 mg 
 
0.55 0.75 0.20 23.5 76.5 
 
3. 
Vaengai 
Pattai 
Thylam 
 
 0.62 1.0 0.37 44.1 55.9 
 
 
Inference:  The test drug has SIGNIFICANT anti-inflammatory action externally. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessment Forms 
ANNEXURE – IV 
ASSESSMENT FORMS 
 
FORM I - SCREENING FORM 
FORM II - CONSENT FORM 
FORM III - CASE  PROFORMA 
FORM IV - LABORATORY INVESTIGATIONS 
FORM V - CLINICAL ASSESSMENT 
FORM VI -  PATIENT WITHDRAWAL FORM 
FORM VII - DRUG COMPLIANCE FORM 
    
       
        
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
AN OPEN CLINICAL TRIAL OF MYELIRAGATHI ENNAI& 
VAENGAIPATTAI THYLAM FOR (UTHIRAVATHASURONITHAM-
RHEUMATOID ARTHRITIS) 
FORM I –SCREENING FORM 
 
1. OP/ IP No:                                                 2. BED No:                    
3. Sl. No:               4.   NAME:  
5. AGE:                                            6. GENDER:  
 7. OCCUPATION:                                         8. SOCIAL STATUS 
9.  DATE OF ADMISSION:                          10. DATE OF DISCHARGE: 
11. POSTAL ADDRESS: 
 
I. INCLUSION CRITERIA: 
• Age: 15- 60  years 
• Sex: Both male and female 
• Symmetrical joint involvement 
• Arthritis of 3 or more joints 
• Rheumatoid factor positive or negative 
• Morning stiffness. 
• Swelling especially in the inter-phalangeal joint. 
• Patients who are willing for admission and stay in IPD for 20 days or 
willing to attend OPD 
• Patient who are willing  to undergo  radiological investigation  and give 
blood and Urine samples for laboratory investigation. 
 
 
 
 
• Patient willing to sign the informed consent stating that he/she will 
consciously stick     to the treatment during 10 days but can opt out of 
the trial of his/her own conscious discretion.  
 
II. EXCLUSION CRITERIA: 
• Hypertension and other Cardiac ailments 
• Diabetes mellitus 
• Narcotics 
• Alcoholics and smokers. 
• Pregnancy and lactation 
• History of trauma 
• Neurological disorder 
• Tuberculosis 
• Any other serious illness 
• Psoriatic arthritis 
• Gouty arthritis. 
 
III. WITHDRAWAL CRITERIA: 
•  Intolerance to the drug and development of adverse reactions during 
drug trial. 
• Poor patient compliance and defaulters. 
• Patient turned unwilling to continue in the course of clinical trial. 
• Occurrence of any adverse reactions. cale. 
 
  
 
 
 
 
GOVERNMENT SIDDHA MEDICAL COLLEGE AND  HOSPITAL 
PALAYAMKOTTAI. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
AN OPEN CLINICAL TRIAL OF MYELIRAGATHI ENNAI AND 
VAENGAIPATTAI  THYLAM FOR(UTHIRAVATHA SURONITHAM-
RHEUMATOID ARTHRITIS) 
Form: II CONSENT FORM 
CERTIFICATE BY INVESTIGATOR 
 I certify that I have disclosed all the details about the study in the terms readily 
understood by the patient. 
Signature………………….          Date……                                                                                                                                                                                                                
Name…………………… 
 
CONSENT BY PATIENT 
I have been informed to my satisfaction, by the attending physician, the 
purpose of the clinical trial, and the nature of drug treatment and follow-up 
including the laboratory investigations to be performed to monitor and safeguard 
my body functions.  
I am aware of my right to opt out of the trial at any time during the course 
of the trial without having to give the reasons for doing so. 
I, exercising my free power of choice, hereby give my consent to be 
included as a subject in the clinical trial of ‘Myeliragathi ennai (Internal drug)’ and 
‘Vaengaipattai thylam (External drug)’ for the treatment of 
‘uthiravathasuronitham’ (Rheumatoid arthritis). 
Signature………………….          Date……………….                                                                                                                                                                                                                
Name………………… 
 
 
 
 
 
 
 
 
 
murpdH rpj;j kUj;Jtf; fy;Y}hp kw;Wk; kUj;Jtkid>ghisaq;Nfhl;il 
gl;lNkw;gbg;G rpwg;GkUj;Jtj;Jiw 
” kw;Wk; ’ ijyk ;” ,tw;wpd; gupfupg;Gj;jpwidf; fz;lwpAk; kUj;Jt Ma;T 
Xg;Gjy; gbtk; 
Ma;thsuhy; rhd;wspf;fg;gl;lJ 
 
 ehd; ,e;j Ma;itf; Fwpj;j midj;J tpguq;fisAk; Nehahspf;F 
GupAk; tifapy; vLj;Jiuj;Njd; vd cWjpaspf;fpNwd;. 
 
Njjp:                                 ifnahg;gk;: 
,lk;:                                   ngau;: 
 
Nehahspapd; xg;Gjy; 
                   
 vd;dplk; ,e;j kUj;Jt Ma;tpd; fhuzj;ijAk; kUe;jpd; jd;ik 
kw;Wk; kUj;Jt topKiwiag; gw;wpAk; njhlu;e;J vdJ cly; ,af;fj;ij 
fz;fhzp;f;fTk>; mjidg; ghJfhf;fTk; gad;gLk; kUj;Jt Ma;Tf;$l 
gupNrhjidfs; gw;wpAk; jpUg;jp mspf;Fk; tifapy; Ma;T kUj;Jtuhy; 
tpsf;fpf; $wg;gl;lJ.  
ehd; ,e;j kUj;Jt Ma;tpd; NghJ fhuzk; vJTk; $whky; 
vg;nghOJ Ntz;LkhdhYk; ,e;j Ma;tpypUe;J vd;id tpLtpj;Jf; 
nfhs;Sk; cupikia njupe;jpUf;fpd;Nwd;. 
 ehd; vd;Dila Rje;jpukhfj; Nju;T nra;Ak; cupikiaf; nfhz;L 
moy; fPy; thA vd;Dk; Neha;f;fhd ‘kapypwfhjp vz;nza; ” kw;Wk;; 
‘Ntq;ifg;gl;il ijyk;“ Mfpatw;wpd;  gupfupg;Gj; jpwidf; fz;lwpAk; 
kUj;Jt Ma;tpw;F vd;id cl;gLj;j xg;Gjy; mspf;fpNwd;. 
 
Njjp:                                     ifnahg;gk;: 
,lk;:                                  ngau;: 
Njjp:                          rhl;rpf;fhuh; ifnahg;gk;: 
,lk;:                                        ngau; 
 
 
 
 
 
GOVERNMENT SIDDHA MEDICAL COLLEGE AND HOSPITAL 
PALAYAMKOTTAI. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
AN OPEN CLINICAL TRIAL OF MYELIRAGATHI ENNAI& 
VAENGAIPATTAI THYLAM FOR UTHIRAVATHASURONITHAM 
(RHEUMATOID ARTHRITIS) 
FORM III – CASE PROFORMA 
1. OP/ IP No:                                           2. BED No:                             3. Sl. No:  
 4.   NAME:                                              5. AGE:                                  6. GENDER:  
 7.   OCCUPATION:                                    8. SOCIAL STATUS 
9.  DATE OF ADMISSION:                        10. DATE OF DISCHARGE: 
11. POSTAL ADDRESS: 
 
12. COMPLAINTS & DURATION:    
13. HISTORY OF PRESENT ILLNESS:  
14. PAST HISTORY:  
15. FAMILY HISTORY: 
16. MENSTRUAL HISTORY (If applicable):  
17. HABITS:                                  Yes               No                                                                                                                                                                                             
1. Smoker     
2. Alcoholic 
3. Betel nut chewer 
4. Non-Veg /Vegetarian      
5. Drug addiction                                 
18. GENERAL EXAMINATION: 
1. Body weight [Kg]         :                      
2. Height [cm]                        :                      
3. Body Temperature [oF]       :   
Lecturer                         HOD 
 
 
 
 
4. Blood Pressure (mmHg) :      
5. Pulse Rate /min.  : 
6. Heart Rate /min.   : 
7. Respiratory Rate /min.  :   
 
                                                        Yes            No   
8. Pallor : 
9. Jaundice :   
10. Clubbing : 
11. Cyanosis : 
12. Pedal Oedema : 
13. Lymphadenopathy    :                                        
14. Jugular venous pulsation:  
19. CLINICAL EXAMINATION OF KNEE JOINT: 
I. INSPECTION                                Present      Absent 
        1. Swelling     …………………………… 
        2. Muscle wasting     …………………………… 
        3. Deformity      …………………………… 
II. PALPATION: Present            Absent 
    1. Tenderness           ………………………….. 
    2. Swelling          ……………………………  
    3. Crepitations           …………………………… 
  4. Warmth                   ……………………………… 
III. MOVEMENTS:  
1. Restriction of Movements in the affected joint:  Full     Partial          No 
2. Affected:  PAIN  MUSCULAR SPASM ROM 
                                             Yes   No        Yes      No           Normal        Reduced 
    i. Flexion       
         ii. Extension 
 
 
 
 
 
3. NEUROLOGICAL EXAMINATION: 
   i. Sensation  Normal                     Abnormal                  
   ii. Tone                         Normal                  Abnormal                   
  iii. Power                      Normal                    Abnormal                  
  iv.Muscle wasting  Present                   Absent                      
4. REFLEXES:                      Normal    Exaggerated  
        i. Knee jerk 
        ii. Ankle jerk 
20. CLINICAL ASSESSMENT: 
I. PAIN: 
A. Pain in the knee joints:       No            Mild                  Moderate         Severe  
       
          i. Onset         Sudden                       Gradual              
         ii. Nature:         Local                           Diffuse        Others 
B. Nature of pain   Shooting                       Burning       Others 
   
   YES                NO 
C. Pain during movements          
II. Morning stiffness 
III.Tenderness                                                                                                                                                                       
III. Swelling             
IV. Restricted joint movements                                                                                              
 
21. EXAMINATION OF OTHER SYSTEMS: 
   Normal       Abnormal 
1.  CVS  
2.  RS    
3.  CNS 
4. ABDOMEN   
          5. GENITO-URINARY                                         
 
 
 
 
SIDDHA ASPECTS 
1. NILAM: 
       1. Kurinji            2. Mullai          3. Marutham       4. Neithal           5. Paalai 
 
2 . KAALAM: 
         1. Kaar Kaalam    2. Koothir Kaalam         3. Munpani Kaalam      
         4. Pinpani Kaalam          5. Ilavenir Kaalam 6. Muduvenir Kaalam 
 
3. YAAKKAI: 
 1. Vatham          2. Pitham      3. Kabam     
4. Vathapitham        5. Pithavatham    6. Kabavatham       
7. Vathakabam        8. Pithakabam              9. Kabapitham    
4. GUNAM: 
 1. Sathuvam  2. Rasatham             3. Thamasam 
5. IYMPORIGAL:    Normal   Affected   
1.  Mei                                   ..………………………………….. 
2. Vaai                                    ……………………………………... 
3.  Kan                                   ……………………………………… 
4. Mookku                             ……………………………………… 
5.  Sevi                                   …………………………………………… 
6. KANMENDHIRIUM / KANMAVIDAYAM: 
   Normal   Affected    
1. Kai                                            …………………………………………... 
2. Kaal                                          …………………………………………... 
3. Vaai                                           ………………………………………….. 
4. Eruvaai                                      …………………………………………..  
5. Karuvaai                                    ………………………………………….. 
 
 
 
 
 
 
7. UYIR THATHUKKAL: 
I. VATHAM:     Normal    Affected 
1. Piraanan                                      ………………………………………… 
2.  Abaanan                                    ………………………………………….    
3. Viyaanan                                 ………………………………………….   
4.  Uthaanan                                    ……………………………………    
5. Samaanan                                    ……………………………………                             
6. Naagan                                      ……………………………………….    
7. Koorman                                  …………………………………………... 
8. Kirukaran                                   …………………………………………...         
9. Devathathan                               …………………………………………     
10. Dhananjeyan                            …………………………………………  
 
II. PITHAM :             Normal    Affected 
1. Analam                                     ……………………………………….         
2. Ranjagam                                 ………………………………………….   
3. Saathagam                                  ………………………………………..     
4. Aalosagam                                 ……………………………………….           
5. Prasagam                                   …………………………………….. 
III. KABAM:     Normal    Affected 
1. Avalambagam                       …………………………………………… 
2. Kilethagam                             …………………………………………… 
3. Pothagam                                 …………………………………………… 
4. Tharpagam                               ……………………………….…………... 
5. Santhigam                                …………………………………………… 
 
 
 
 
8. UDAL THATHUKKAL: Normal   Affected 
1.  Saaram                                                     ……………………………… 
2. Senneer                                                ……………………………… 
3.  Oon                                                                 ……………………………. 
4.  Kozhuppu                                                       ……………………………. 
5. Enbu                                                                ……………………………. 
6. Moolai                                                             …………………………… 
7. Sukkilam/Suronitham                                   ……………………………. 
9. ENVAGAI THERVUGAL: 
 1 . Naadi    ……………………………………………………. 
                              Normal    Affected 
2. Sparisam                                           ………………………….. 
3. Naa                                                       …………………………… 
4. Niram                                            …………………………….. 
5. Mozhi                                                      …………………………….. 
6. Vizhi                                                        …………………………….. 
7. Malam 
      a. Niram                                  …………………………….. 
      b. Nurai                                   …………………………….. 
      c. Kirumi                    .…………………………….. 
      d. Thanmai:    i. Irugal                 ii. Ilagal                           
 8. Moothiram: 
I. NEERKKURI   Normal    Affected 
     a. Niram                             …………………………….. 
     b . Manam                      …              …………………………….. 
     c. Edai                       …………………………….. 
     d. Nurai                    …………………………….. 
     e. Enjal                                             …………………………….. 
II. NEIKKURI: ………………………………………. 
          Vatha Neer             Pitha Neer            Kaba Neer 
 
 
 
 
GOVERNMENT SIDDHA MEDICAL COLLEGE AND  HOSPITAL 
PALAYAMKOTTAI. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
AN OPEN CLINICAL TRIAL OF MYELIRAGATHI ENNAI& 
VAENGAIPATTAI THYLAM FOR UTHIRAVATHASURONITHAM 
(RHEUMATOID ARTHRITIS) 
Form IV - LABORATORY INVESTIGATIONS 
1. OP/ IP No:                                                 2. BED No:                           3. Sl. No:  
 4.   NAME:                                                      5. AGE:                                 6. GENDER:  
 7.   OCCUPATION:                                        8. SOCIAL STATUS 
9.  DATE OF ENROLMENT:                        10. DATE OF DISCHARGE: 
11. POSTAL ADDRESS: 
 
Date: 
I. BLOOD: 
1. TC :    (Cells/Cumm)          
2. DC (%):   N                L                        M             E                      
3. ESR (mm) :    ½ hr                           1 hr 
4. Hb:       RA factor-       CRP-  
5. Total RBC:                
6. Blood Sugar:   a) Fasting                       b) Post prandial                        
7. Kidney function tests: 
              Blood urea:   Serum creatinine: 
8. Lipid profile: 
              HDL:   LDL:              VLDL:   
              Total Cholesterol :  TGL: 
9. Liver Function tests: 
              SGOT:   SGPT:  Alk. Phosphatase: 
               Albumin:  Globulin:  Total Protein: 
               Serum Bilirubin:         Total  Direct  Indirect : 
Lecturer                         HOD 
 
 
 
 
      II. URINE:       
1. Albumin  :       
2. Sugar   :          
3. Epithelial cells    :                 
4. Pus cells             :                 
5. Red blood cells   :                 
6. Casts/Crystals     : 
 
III. MOTION: 
Ova     : 
Cyst     : 
Occult blood    : 
Pus cells    : 
 
IV. X-RAY: 
  
 
 
 
 
GOVERNMENT SIDDHA MEDICAL COLLEGE AND  HOSPITAL 
PALAYAMKOTTAI. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
AN OPEN CLINICAL TRIAL OF UTHIRAVATHASURONITHAM & 
VAENGAIPATTAI  THYLAM FOR UTIRAVATHASURONITHAM 
(RHEUMATOID ARTHRITIS) 
FORM V – CLINICAL ASSESSMENT 
1.  OP/ IP No:                                                 2. BED No:                           3. Sl. No:  
 4.   NAME:                                                      5. AGE:                                 6. GENDER:  
 7.   OCCUPATION:                                        8. SOCIAL STATUS 
9.  DATE OF ADMISSION:                          10. DATE OF DISCHARGE: 
11. POSTAL ADDRESS: 
 
CLINICAL EXAMINATION OF  JOINTS: 
I. INSPECTION:                    Present      Absent 
        1. Swelling     …………………………… 
        2. Muscle wasting     …………………………… 
        3. Deformity      …………………………… 
II. PALPATION: Present            Absent 
    1. Tenderness            ……………………… 
    2. Swelling              …………………………  
    3. Crepitations     ……………………………… 
  4. Warmth               ……………………………… 
III. MOVEMENTS:  
1. Restriction of Movements in the affected joints:  Ful      Partial            No 
2. MOVEMENTS OF THE AFFECTED JOINTS: 
                                                 Yes   No        Yes   No                Normal    Reduced 
            i. Flexion  
            ii. Extension 
 
Lecturer                         HOD 
 
 
 
 
3. NEUROLOGICAL EXAMINATION: 
             i. Sensation: Normal                             Abnormal                …………... 
             ii. Tone         Normal                          Abnormal                  ………….. 
             iii. Power      Normal                            Abnormal               ..………… 
             iv. Muscle wasting:  Present              Absent              …………. 
4. REFLEXES:               Normal   Exaggerated  
        i. Knee jerk 
        ii. Ankle jerk 
20. CLINICAL ASSESSMENT: 
I. PAIN: 
A. Pain in the knee joints:      No                Mild          Moderate         Severe  
         i. Onset              Sudden                          Gradual              
         ii. Nature:           Local                         Diffuse          Others 
B. Nature of pain       Shooting                         Burning          Others     
       Yes                  No 
C. Pain during movements     
II. Morning stiffness 
III.Tenderness                                                                                                                                                                     
III. Swelling             
IV. Restricted joint movements                                                                                           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GOVERNMENT SIDDHA MEDICAL COLLEGE AND HOSPITAL 
PALAYAMKOTTAI. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
AN OPEN CLINICAL TRIAL OF MYELIRAGATHI ENNAI 
&VAENGAIPATTAI  THYLAM FOR UTHIRAVATHASURONITHAM 
(RHEUMATOID ARTHRITIS) 
FORM - VI PATIENT WITHDRAWAL FORM 
1.  OP / IP No       …………    2. S.No. ………………     3.Date: …………… 
4.  Name    ………………….. 5. Age ……………           6. Gender ………… 
7.  Postal address: 
---------------------------------------------------------------------------------------------------- 
Complaints and Duration: 
 
Irregular treatment: 
 
Other causes: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GOVERNMENT SIDDHA MEDICAL COLLEGE AND HOSPITAL 
PALAYAMKOTTAI. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
AN OPEN CLINICAL TRIAL OF MYELIRAGATHI ENNAI 
&VAENGAIPATTAI  THYLAM FOR UTIRAVATHASURONITHAM 
(RHEUMATOID ARTHRITIS) 
FORM VII - DRUG COMPLIANCE FORM 
Name of the Drug: MYELIRAGATHI ENNAI drug is issued: ………… (ml) 
Drugs returned:  ……………(ml) 
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                    Signature of the HODS 
 
 
 
 
S.NO DATE 
DRUG TAKEN TIME 
MORNING/TI
ME 
AFTERNOON/TI
ME 
NIGHT/TIM
E 
Day 1     
Day 2     
Day 3     
Day 4     
..     
..     
Up to day 
48 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
